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ABSTRACT OF DISSERTATION 
 
 
 
NOVEL APPLICATIONS OF MACHINE LEARNING IN BIOINFORMATICS 
 
 
Technological advances in next-generation sequencing and biomedical imaging 
have led to a rapid increase in biomedical data dimension and acquisition rate, which is 
challenging the conventional data analysis strategies. Modern machine learning techniques 
promise to leverage large data sets for finding hidden patterns within them, and for making 
accurate predictions. This dissertation aims to design novel machine learning-based models 
to transform biomedical big data into valuable biological insights. The research presented 
in this dissertation focuses on three bioinformatics domains: splice junction classification, 
gene regulatory network reconstruction, and lesion detection in mammograms. 
A critical step in defining gene structures and mRNA transcript variants is to 
accurately identify splice junctions. In the first work, we built the first deep learning-based 
splice junction classifier, DeepSplice. It outperforms the state-of-the-art classification tools 
in terms of both classification accuracy and computational efficiency. To uncover 
transcription factors governing metabolic reprogramming in non-small-cell lung cancer 
patients, we developed TFmeta, a machine learning approach to reconstruct relationships 
between transcription factors and their target genes in the second work. Our approach 
achieves the best performance on benchmark data sets. In the third work, we designed deep 
learning-based architectures to perform lesion detection in both 2D and 3D whole 
mammogram images. 
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CHAPTER 1. INTRODUCTION 
 
1.1 Machine learning 
Machine learning can be broadly described as computational methods using 
previous experience to improve performance or to make precise inferences. Here, previous 
experience refers to the past information available to the learner. This data could be in the 
form of digitized human-labeled training sets, or other types of information obtained via 
interaction with the environment. In all cases, its quality and size are crucial to the success 
of the predictions made by the learner [1]. 
The processes involved in machine learning are similar to that of data mining and 
predictive modeling. Both require searching through data to look for patterns and adjusting 
program actions accordingly. Many people are familiar with machine learning from 
shopping on the internet and being served ads related to their purchase. This happens 
because recommendation engines use machine learning to personalize online ad delivery 
in almost real time. Beyond personalized marketing, other common machine learning use 
cases include fraud detection, spam filtering, network security threat detection, predictive 
maintenance and building news feeds. 
Machine learning algorithms are often categorized as supervised or unsupervised. 
Supervised algorithms require both input and desired output, in addition to furnishing 
feedback about the accuracy of predictions during algorithm training. Once training is 
complete, the algorithm will apply what was learned to new data. Unsupervised algorithms 
do not need to be trained with desired outcome data. 
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Since the success of a learning algorithm depends on the data used, machine 
learning is inherently related to data analysis and statistics. More generally, machine 
learning techniques are data-driven methods combining fundamental concepts in computer 
science with ideas from statistics, probability and optimization [1]. 
The standard machine learning tasks which have been extensively studied are listed 
as follows: 
 Classification: classification is used when the outputs are restricted to a limited set 
of values. For a classification task that filters emails, the input would be an incoming 
email, and the output would be the name of the folder in which to file the email [2]. 
 Regression: regression is adopted to predict continuous outputs, that is, real values 
within a range. Examples of a continuous value are the temperature, length, or price 
of an object [2]. 
 Ranking: ranking is to produce a permutation of items in unseen lists in a way which 
is similar to rankings in the training data in some sense. Ranking is a central part of 
many information retrieval problems, such as document retrieval, sentiment analysis, 
and online advertising [3]. 
 Clustering: clustering is the task of grouping a set of objects in such a way that 
objects in the same group are more similar to each other than to those in other groups. 
For instance, in social network analysis, clustering algorithms try to identify natural 
communities within a large group of people [4]. 
 Dimensionality reduction: dimensionality reduction is to transform an initial 
representation of items into a lower-dimensional representation while preserving some 
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properties of the initial representation. A common example involves preprocessing 
digital images in computer vision tasks [1]. 
 
1.2 Deep learning 
Deep learning is a branch of machine learning, which employs numerous similar 
but distinct deep neural network architectures to solve various problems in natural language 
processing, computer vision, and bioinformatics, among other fields. Deep learning has 
experienced tremendous recent research resurgence, and has been shown to deliver state of 
the art results in numerous applications. 
In essence, deep learning is the implementation of neural networks with more than 
a single hidden layer of neurons, as shown in Figure 1.1. However, this is a very simplistic 
view of deep learning, and not one that is unanimously agreed upon. These "deep" 
architectures also vary quite considerably, with different implementations being optimized 
for different tasks or goals. The vast research being produced at such a constant rate is 
revealing new and innovative deep learning models at an ever-increasing pace. 
The successes of deep learning are built on a foundation of significant algorithmic 
details and generally can be understood in two parts: construction and training of deep 
learning architectures [5]. Deep learning architectures are basically artificial neural 
networks of multiple non-linear layers and several types have been proposed according to 
input data characteristics and research objectives. Here, we categorized deep learning 
architectures into four groups: deep neural networks (DNNs), convolutional neural 
networks (CNNs), recurrent neural networks (RNNs) and emergent architectures. DNNs 
include multilayer perceptron (MLP), stacked auto-encoder (SAE) and deep belief 
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networks (DBNs), which use perceptrons, auto-encoders and restricted Boltzmann 
machines as the building blocks of neural networks, respectively. CNNs are architectures 
that have succeeded particularly in image recognition and consist of convolution layers, 
non-linear layers and pooling layers. RNNs are designed to utilize sequential information 
of input data with cyclic connections among building blocks like perceptrons, long short-
term memory units or gated recurrent units. In addition, many other emergent deep learning 
architectures have been suggested, such as deep spatio-temporal neural networks (DST-
NNs), multidimensional recurrent neural networks (MD-RNNs) and convolutional auto-
encoders (CAEs). 
 
 
 
Figure 1.1  Illustration of the deep neural network layers. 
 
The goal of training deep learning architectures is optimization of the weight 
parameters in each layer, which gradually combines simpler features into complex features 
so that the most suitable hierarchical representations can be learned from data. A single 
cycle of the optimization process is organized as follows. First, given a training dataset, 
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the forward pass sequentially computes the output in each layer and propagates the function 
signals forward through the network. In the final output layer, an objective loss function 
measures error between the inferred outputs and the given labels. To minimize the training 
error, the backward pass uses the chain rule to backpropagate error signals and compute 
gradients with respect to all weights throughout the neural network. Finally, the weight 
parameters are updated using optimization algorithms based on stochastic gradient descent 
(SGD). Whereas batch gradient descent performs parameter updates for each complete 
dataset, SGD provides stochastic approximations by performing the updates for each small 
set of data examples. Several optimization algorithms stem from SGD. For example, 
Adagrad and Adam perform SGD while adaptively modifying learning rates based on 
update frequency and moments of the gradients for each parameter, respectively. 
Another core element in the training of deep learning architectures is regularization, 
which refers to strategies intended to avoid overfitting and thus achieve good 
generalization performance. For example, weight decay, a well-known conventional 
approach, adds a penalty term to the objective loss function so that weight parameters 
converge to smaller absolute values. Currently, the most widely used regularization 
approach is dropout. Dropout randomly removes hidden units from neural networks during 
training and can be considered an ensemble of possible subnetworks. Furthermore, recently 
proposed batch normalization provides a new regularization method through normalization 
of scalar features for each activation within a mini-batch and learning each mean and 
variance as parameters. 
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1.3 Machine learning in bioinformatics 
In the era of big data, the rapid increase in biomedical data dimension and 
acquisition rate is challenging conventional analysis strategies. Modern machine learning 
methods, such as deep learning, promise to leverage large data sets for finding hidden 
structure within them, and for making accurate predictions. 
The potential of machine learning in analyzing biomedical data sets is clear: in 
principle, it allows to better exploit the availability of increasingly large and high-
dimensional data sets by training complex models that capture their internal structure. The 
learned models discover high-level features, increase interpretability and provide 
additional understanding about the structure of the biomedical data [6]. 
Recent papers are trying to apply machine learning to omics, biomedical imaging, 
electronic health record, and numerous other bioinformatics domains. 
 
1.3.1 Omics 
Improvements in technology have fueled the proliferation of omics applications. 
These techniques are often used to measure and study complex biological systems and their 
interactions. Omics includes a multitude of areas of focus such as genomics, 
transcriptomics, proteomics, interactomics, metabolomics, phenomics, and 
pharmacogenomics to name, but a few. Each one of these areas might also have many 
subdomains, each requiring further specialization in analytical and computational 
approaches [7]. 
Increasingly, the scale of omics data generation has been challenging researchers' 
abilities to integrate and model often noisy, complex, and high-dimensional data. Machine 
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learning has emerged as a powerful approach, which can both encode and model many 
forms of complex data both in supervised and unsupervised settings. DeepBind has been 
built to predict the sequence specificities of DNA- and RNA-binding proteins by deep 
learning [8]. Chen et al. [9] designed a machine learning-based method, D-GEX, to infer 
the expression of target genes from the expression of landmark genes. Arvaniti et al. 
proposed CellCnn [10], a representation learning approach to detect rare cell subsets 
associated with disease using high-dimensional single-cell measurements. Ma et al. 
developed DCell [11], a visible neural networks embedded in the hierarchical structure of 
2,526 subsystems comprising a eukaryotic cell. Trained on several million genotypes, 
DCell simulates cellular growth nearly as accurately as laboratory observations. Altae-Tran 
et al. [12] introduced a new deep-learning architecture, the iterative refinement long short-
term memory, a modification of the matching-networks architecture and the residual 
convolutional network. The architecture allows for the learning of sophisticated metrics 
which can trade information between evidence and query molecules. The authors 
demonstrated that their architecture offers significant boosts in predictive power for a 
variety of problems meaningful for low-data drug discovery. 
 
1.3.2 Biomedical imaging 
Over the recent years, machine learning has had a tremendous impact on various 
fields in science. It has led to significant improvements in speech recognition and image 
recognition, it is able to train artificial agents that beat human players in Go and ATARI 
games, and it creates artistic new images, and music. Many of these tasks were considered 
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to be impossible to be solved by computers [13]. Obviously this technology is also highly 
relevant for biomedical imaging. 
The advantage of machine learning in an era of biomedical imaging big data is that 
significant hierarchal relationships within the data can be discovered algorithmically 
without laborious hand-crafting of features. The key machine learning applications in 
biomedical imaging include image classification, localization and detection, segmentation, 
and image reconstruction. Esteva et al. [14] demonstrated the effectiveness of deep 
learning in dermatology, a technique applied to both general skin conditions and specific 
cancers. Using a single convolutional neural network trained on general skin lesion 
classification, the authors matched the performance of at least 21 dermatologists tested 
across three critical diagnostic tasks: keratinocyte carcinoma classification, melanoma 
classification and melanoma classification using dermoscopy. Chlebus et al. [15] 
developed a fully automatic method for liver tumor segmentation in CT images based on a 
2D fully convolutional neural network with an object-based postprocessing step. Inspired 
by the sharp, high texture-quality images retrieved by GANs, and the high contrast of MR 
images, Mardani et al. [16] employed GANs for modeling the low-dimensional manifold 
of high-quality MR images. This framework can leverage the historical data for rapid and 
high diagnostic-quality image reconstruction from highly undersampled MR 
measurements. 
 
1.3.3 Electronic health record 
Over the past 10 years, hospital adoption of electronic health record (EHR) systems 
has skyrocketed, in part due to the Health Information Technology for Economic and 
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Clinical Health (HITECH) Act of 2009, which provided $30 billion in incentives for 
hospitals and physician practices to adopt EHR systems [17]. According to the latest report 
from the Office of the National Coordinator for Health Information Technology (ONC), 
nearly 84% of hospitals have adopted at least a basic EHR system, a 9-fold increase since 
2008 [18]. Given the increasingly vast amount of patient data and the rise in popularity of 
machine learning approaches, there has also been an increase in the number of publications 
applying machine learning to EHR data for clinical informatics tasks which yield better 
performance than traditional methods and require less time-consuming preprocessing and 
feature engineering. 
Miotto et al. [19] presented a novel unsupervised deep feature learning method to 
derive a general-purpose patient representation from EHR data that facilitates clinical 
predictive modeling. In particular, a three-layer stack of denoising autoencoders was used 
to capture hierarchical regularities and dependencies in the aggregated EHRs. The authors 
reported that their findings indicate that deep learning applied to EHRs can derive patient 
representations that offer improved clinical predictions, and could provide a machine 
learning framework for augmenting clinical decision systems. Rajkomar et al. [20] 
proposed a representation of patients’ entire raw EHR records based on the Fast Healthcare 
Interoperability Resources (FHIR) format. The authors demonstrated that deep learning 
methods using their representation are capable of accurately predicting multiple medical 
events from multiple centers without site-specific data harmonization, and their models 
outperformed traditional, clinically-used predictive models in all cases. Chen et al. [21] 
developed NoteAid, a natural language processing system that links medical terms in EHR 
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notes to lay definitions targeted at or below the average adult literacy level to support 
patient EHR comprehension. 
 
1.4 Dissertation statement 
This dissertation aims to design novel machine learning-based models to transform 
biomedical big data into valuable biological insights. It covers three different but closely 
related bioinformatics domains of great importance, including: classification of splice 
junction sequences using convolutional neural networks, reconstruction of gene regulatory 
networks using gradient boosted trees, and detection of lesions in mammogram images 
using deep learning. 
 
1.5 Contributions of this dissertation 
We have developed a series of novel machine learning-based approaches for 
analyzing various biomedical data, including genomics data, transcriptomics data, and 
biomedical imaging data. The performance of each of those approaches is assessed using 
a number of simulated and real datasets. The experiments demonstrate their advantages on 
accuracy and efficiency compared to other state-of-the-art approaches. This dissertation 
may contribute to the following three areas. 
 Accurate classification of novel splice junctions derived from RNA-seq 
alignment A model inferred from the sequences of annotated exon junctions 
that can then classify splice junctions derived from primary RNA-seq data has been 
developed. Our DeepSplice model is the first deep learning-based splice junction 
classifier. The performance of the model was evaluated and compared through 
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comprehensive benchmarking and testing, indicating a reliable performance and gross 
usability for classifying novel splice junctions derived from RNA-seq alignment. Our 
findings further indicate that valuable information is present in the nucleotide 
sequence local to the splice junction, data that conventional splice site prediction 
techniques discard. 
 Efficient reconstruction of gene regulatory networks using multi-omics data 
sets Leveraging gradient boosted trees, a multi-omics approach to uncover TFs 
governing cancer metabolic reprogramming and reconstruct their interactions with 
metabolic enzymes has been designed. We demonstrated that TFmeta achieved state-
of-the-art performance in recovering TF-target gene interactions on public benchmark 
data sets. We applied our model to non-small-cell lung cancer patients’ data sets to 
predict TFs modulating the dysregulation of glycolysis in lung cancer, leveraging the 
pairing information of the samples and TF DNA binding activities. Eventually, we 
predicted a list of key TFs that may motivate the upregulation of glycolysis observed 
in tumor cells, some of which have been supported by literature evidence, and some 
of which were predicted as novel putative TFs in lung cancer. 
 Precise detection of lesions in 2D and 3D mammography images We 
conducted the first work that study both 2D and 3D mammography images for breast 
cancer classification through deep learning. We evaluated ten different convolutional 
neural network architectures and concluded that combining both data augmentation 
and transfer learning methods with a convolutional neural network is the most 
effective in improving classification performance. Our work sheds light on how each 
type of data sets performs when trained independently. 2D and 3D images are 
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complementary to each other, where 2D offers high resolution while 3D offers 
multiple views. Our work suggests the development of assembled classifiers that 
integrate the 2D and 3D data to achieve optimal performance. 
The software packages for the algorithms developed in this dissertation are open 
source and publicly available to the research community. 
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CHAPTER 2. DISCERNING NOVEL SPLICE JUNCTIONS REVEALED BY RNA-SEQ WITH 
DEEPSPLICE 
Exon splicing is a regulated cellular process in the transcription of protein-coding 
genes. Technological advancements and cost reductions in RNA sequencing have made 
quantitative and qualitative assessments of the transcriptome both possible and widely 
available. RNA-seq provides unprecedented resolution to identify gene structures and 
resolve the diversity of splicing variants. However, currently available ab initio aligners 
are vulnerable to spurious alignments due to random sequence matches and sample-
reference genome discordance. As a consequence, a significant set of false positive exon 
junction predictions would be introduced, which will further confuse downstream analyses 
of splice variant discovery and abundance estimation. 
In this chapter, we present a deep learning based splice junction sequence classifier, 
named DeepSplice [22], which employs convolutional neural networks to classify 
candidate splice junctions. We show (I) DeepSplice outperforms state-of-the-art methods 
for splice site classification when applied to the popular benchmark dataset HS3D, (II) 
DeepSplice shows high accuracy for splice junction classification with GENCODE 
annotation, and (III) the application of DeepSplice to classify putative splice junctions 
generated by Rail-RNA alignment of 21,504 human RNA-seq data significantly reduces 
43 million candidates into around 3 million highly confident novel splice junctions. 
 
2.1 Introduction 
Technological improvements, reduced cost, and accessibility of RNA sequencing 
technologies have provided unprecedented visibility of the transcriptome through the deep 
sequencing of all mRNA transcripts present in a sample. Through analyses of mRNA-seq 
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data, researchers now believe that 92–94% of mammalian protein-coding genes undergo 
alternative splicing, with roughly 86% of these containing a minor transcript isoform 
frequency of at least 15% in certain cell types, developmental time points, physiological 
states, or other conditions [23]. This is an 87-89% increase from forty years ago when 
alternative exon structures from a single gene locus were first introduced and it was 
believed that only around 5% of genes in higher eukaryotes undergo alternative splicing 
[24]. 
The approach to defining exon junctions from RNA-seq data utilizes the subset of 
reads that have a gapped alignment to the reference genome. These reads can be aligned to 
two or more exons, indicating that there exist junctions joining adjacent exons. Whereas 
some mapping strategies [25-28] require pre-defined structural annotation of exon 
coordinates, more recently developed algorithms [29-33] can conduct ab initio alignment, 
which means that they do not rely on the existence of predetermined gene structure 
annotation and can potentially identify novel splice junctions between exons by the 
evidence of spliced alignments. 
The accurate prediction of exon junctions is essential for defining gene structures 
and mRNA transcript variants. Splicing must be absolutely precise because the deletion or 
addition of even a single nucleotide at the splice junction would throw the subsequent 
three-base codon translation of the RNA out of frame [34]. However, novel splice junctions 
predicted by read alignments are not totally reliable, since the possibility of randomly 
mapping a short read up to 150 bases to the large reference genome is high [35], especially 
when gapped alignments with short anchoring sequences are permitted. In a recent report 
by Nellore et al [36] that investigated splicing variation, 21,504 RNA-seq samples from 
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the Sequenced Read Archive (SRA) were aligned to the human hg19 reference genome 
with Rail-RNA [37], identifying 42 million putative splice junctions in total. This value is 
125 times the number of total annotated splice junctions in humans, making it impossible 
to admit that all of them actually exist. False positive splice junctions may lead to false 
edges in splice graphs, significantly increasing the complexity of the graphical structures 
[38]. Consequentially, this will impact the accuracy of splice variant inference algorithms 
as they often start from splice graphs derived from RNA-seq alignment [39].  
Conventional strategies designed to filter out false positive exon splice junctions 
depend primarily on two properties: (1) the number and the diversity of reads mapped to 
the given splice junction [35]; and/or (2) the number of independent samples in which the 
specific exon splice junction is identified [35, 40]. In general, higher read support and 
sample reoccurrence rate both enlarge the likelihood of being a true splice junction. These 
criteria have a positive correlation with the number of read alignments, which are 
dependent on the sampling depth of the particular sample. Exact thresholds are difficult to 
set due to varying sampling depth across samples. Additionally, due to both sequencing 
and alignment errors, a splice junction with both high read support and high sample 
reoccurrence may still be the result of systematic bias. In contrast, a splice junction that 
exists in a transcript with relatively low expression may still be functionally important [41]. 
Thus, further classification of putative splice junctions revealed by RNA-seq data is still 
necessary but remains a challenging issue. 
Since the 1980s, a number of bioinformatic approaches have been developed for 
splice site prediction. Neural networks [42-44], support vector machines [45-47], hidden 
Markov model [48-50], deep Boltzmann machines [51] and discriminant analysis [52, 53] 
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have been applied to recognize splice sites in the reference genome of many given species. 
Neural networks, support vector machines and deep Boltzmann machines learn the 
complex features of neighborhoods surrounding the consensus dinucleotide AG/GT by a 
non-linear transformation. Hidden Markov models estimate position specific probabilities 
of splice sites by computing the likelihoods of candidate signal sequences. The 
discriminant analysis uses several statistical measures to evaluate the presence of specific 
nucleotides, recognizing splice sites without explicitly determining the probability 
distributions [50]. However, all these work treat donor and acceptor sites as independent 
events, failing to leverage the inherent relationships between the donor and acceptor during 
splicing.  
In this work, we develop a deep neural network-based approach to the classification 
of potential splice junctions. Our method is applicable to both splice site prediction and 
splice junction classification. First, instead of treating donor or acceptor splice sites 
individually, our method models the donor and acceptor splice sites as a functional pair. 
Thus, it is capable of capturing the remote relationships between features in both donor and 
acceptor sites that determine the splicing. Additionally, flanking subsequences from both 
exonic and intronic sides of the donor and acceptor splice sites will be used for learning 
and prediction, making it possible to understand the contribution of both coding and non-
coding genomic sequences to the splicing. Our approach does not rely on sequencing read 
support or frequency of occurrence derived from experimental RNA-seq data sets, thus can 
be applied as an independent evidence for splice junction validation. Our experiments 
demonstrate that DeepSplice outperforms other state-of-the-art approaches [50, 54-58] 
when tested against a benchmarking dataset, Homo Sapiens Splice Sites Database (HS3D), 
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using a variety of evaluation metrics. Trained on an older version of the GENCODE project 
gene annotation data [59], we show that our algorithm can predict the newly annotated 
splice junctions with high accuracy and performs better than splice site-based approach. 
The application of DeepSplice to further classify putative intropolis human splice junction 
data by Nellore et al [36] is able to eliminate around 83% unannotated splice junctions. We 
discover that the combinational information from the functional pairing of donor and 
acceptor sites facilitates the recognition of splice junctions and demonstrate from large 
amounts of sequencing data that non-coding genomic sequences contribute much more 
than coding sequences to the location of splice junctions [47, 60]. 
 
2.2 DeepSplice method 
DeepSplice employs a convolutional neural network (CNN, or ConvNet) to 
understand sequence features that characterize real splice junctions [61]. The overall 
architecture of DeepSplice is shown in Figure 2.1. In the supervised training step, CNN 
learns features that help to differentiate actual splice junctions from fake ones. In the 
inference step, the trained model uses the genomic sequence of the candidate splice 
junction and predicts the probability of it being a real splice junction. Deep Taylor 
decomposition [62] of the CNN is used to explain to what extent each nucleotide in the 
candidate splice junction has contributed to the inference. 
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Figure 2.1  Visualization of splice junction sequence representation and deep convolutional 
neural network in DeepSplice. Each sequence is converted into a tensor through one-hot 
encoding in the pre-processing of the sequence representation. The tensor is fed as original 
input to the deep convolutional neural network, which contains one input layer, two 
convolutional layers, one fully connected layer (FCN) and one output layer. The 
convolutional neural network transforms the nucleotide signal in splice junction sequences 
to the final label of class. 
 
2.2.1 Splice junction representation 
A splice junction sequence is represented by four subsequences, the upstream 
exonic subsequence and downstream intronic subsequence at the donor site, and the 
upstream intronic subsequence and downstream exonic subsequence at the acceptor site, 
as shown in Figure 2.1. Each subsequence has the length of 30, which is believed to be 
optimal for splice site/junction prediction [41, 44, 48, 49, 63]. Nucleotides in each sequence 
are represented through one-hot encoding. In the proposed encoding system, the 
orthonormal sparse encoding is used for the four definite values (A, C, G and T) as it has 
been used widely in the numerical representations of biological sequences [64]. But for the 
ambiguous base N, instead of disregarding it or giving it the same importance as the definite 
values, the probability is used. 
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Each splice junction sequence is transformed into a 3-dimensional tensor. The first 
dimension ‘height’ is equal to one, and the second dimension ‘width’ indexes the sequence 
length, that is, the number of nucleotides in the sequence, and the third dimension 
‘channels’ indexes the type of nucleotide. The tensors are fed as input to deep convolutional 
neural networks for downstream processing. 
 
2.2.2 Deep convolutional neural network 
DeepSplice contains a multi-layer feedforward neural network. We stack one input 
layer, two convolutional layers, one fully connected layer, and one output layer. The whole 
network architecture can be written as follows:  
𝐿𝑎𝑏𝑒𝑙 𝑜𝑓 𝑐𝑙𝑎𝑠𝑠 = 𝑓𝑓𝑐𝑛(𝑓𝑐𝑜𝑛𝑣2(𝑓𝑐𝑜𝑛𝑣1(𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 𝑛𝑢𝑐𝑙𝑒𝑜𝑡𝑖𝑑𝑒 𝑠𝑖𝑔𝑛𝑎𝑙)). 
In this way, the convolutional neural network transforms the nucleotide signal in splice 
junction sequences to the final label of class as shown in Figure 2.1. 
In the first convolutional layer, the convolution will compute 8 features over the 
input tensor which represents splice junction sequence, which results in 8 feature maps of 
the input tensor. In order to reason the complex nonlinearity between inputs and outputs, 
we further stack the second convolutional layer computing 16 features over 8 feature maps 
from the first convolutional layer. In the convolutional layers, the filters have size 3x1. 
During the forward pass, we slide each filter along the splice junction sequence and 
compute dot products between the filter and the input tensor. As we slide the filter over the 
input splice junction sequence we will produce feature maps that give the responses of that 
filter at every spatial position. After two convolutional layers, the features are presented in 
16 tensors. The output of the second convolutional layer is taken by a fully connected layer 
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with 32 feature maps for high-level reasoning. The fully connected layer is followed by the 
output layer indicating the final label of class. In the neural network, all parameters are 
learned during training to minimize a loss function which captures the difference between 
the true labels of class and predicted values. 
Training the network follows the standard backpropagation and optimizes the loss 
function using Adam [65]. Advance deep learning techniques L2 regularization [66], 
dropout [67] and mini-batch gradient descent [68] are deployed to regularize the network 
to prevent over-fitting and to accelerate the training process. 
In the reference step, testing splice junction sequences transformed by one-hot 
encoding are fed to the learned network for a binary classification, which outputs the 
predicted label of the class, true or false splice junction. 
 
2.2.3 Deep Taylor decomposition of deep convolutional neural network 
We propose to use deep Taylor decomposition [62] to explain the contribution of 
nucleotides in the splice junction sequence to the final decision function of the deep 
convolutional neural network, as shown in Figure 2.2. Taking image recognition task as an 
example, such decomposition results in a “heat map” that indicates what pixels of the image 
are important for a neural network classification. In our application, for testing splice 
junction sequence 𝐒, we would like to associate to nucleotide 𝑛 a contribution score 𝐶𝑛(𝐒) 
from which it is possible to judge which nucleotides are of importance to explain the 
predicted label of class from the deep convolutional neural network. 
Deep Taylor decomposition operates by running a backward pass on the trained 
convolutional neural network using a predefined set of rules. Backpropagating from the 
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function output down to the input, it results in assigning a set of scores 𝐂(𝐒) = {𝐶𝑛(𝐒)} to 
the nucleotides in the input testing splice junction sequence 𝐒 to quantify their contributions 
to the predicted label of class. 
 
 
 
Figure 2.2  Visualization of deep Taylor decomposition in DeepSplice. Deep Taylor 
decomposition explains the contribution of each nucleotide in the splice junction sequence 
to the final decision function of the deep convolutional neural network. Deep Taylor 
decomposition operates by running a backward pass on the trained convolutional neural 
network using a predefined set of rules. 
 
2.2.4 Other deep learning architectures 
To decipher the abilities of different deep learning architectures in handling splice 
junction sequence data, we further build multilayer perceptron network (MLP) and long 
short-term memory network (LSTM) to compare with convolutional neural network. MLP 
is a feedforward artificial neural network with multiple hidden layers of units between input 
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and output layers. LSTM is a recurrent neural network architecture where connections 
between units form a directed cycle. 
The multilayer perceptron network is composed of one input layer, four hidden 
layers and one output layer. Each layer is fully connected to next layer in the network. The 
number of neurons in each hidden layer is 64, 128, 128 and 256 respectively. In the long 
short-term memory network, we deploy one input layer, three hidden layers and one output 
layer. Each of the three hidden layers contains 16 LSTM cells. For both architectures, the 
inputs are splice junction sequences transformed by one-hot encoding, and the outputs are 
class labels. Advance deep learning techniques, dropout [67], regularization [66], mini-
batch gradient descent [68] and Adam [65], are exploited in the supervised training steps 
in both networks. 
 
2.2.5 Filtering of false splice junction as a result of repetitive sequences 
One potential resource of false positive splice junction is the inability to align a 
sequence to the correct sites due to higher mismatches than the threshold set by aligners or 
small indels that cannot be detected by aligners. Before the classification of splice 
junctions, we first remove the splice junctions whose sequence at the acceptor (donor) site 
has high sequence similarity with the immediate flanking sequence next to the donor 
(acceptor) site or the sequence at any of its alternative acceptor (donor) sites, as shown in 
Figure 2.3. The edit distance between the alternative acceptor (donor) site sequences is 
computed using the Smith-Waterman algorithm [69]. This filtering strategy is independent 
of read coverage and enables the retention of correct splice junctions even with low read 
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coverage. The removal of these sequences is necessary as most of them are highly similar 
with one of the splice junctions remaining in the data set. 
 
 
 
Figure 2.3  Illustration of splice junction filtering strategy. In this example, two edit 
distances are calculated. One (Ed) is between anchor sequence at donor site (G[Jd-
Ad+1:Jd]) and intermediate flanking sequence next to acceptor site (G[Ja-Aa:Ja-1]). The 
other (Ea) is between anchor sequence at acceptor site (G[Ja:Ja+Aa-1]) and intermediate 
flanking sequence next to donor site (G[Jd+1:Jd+Ad]). 
 
2.2.6 Implementation and performance measures 
The deep learning architectures are implemented using TensorFlow [70]. Training 
and testing are deployed on Nvidia GeForce GTX 1080 graphics cards. DeepSplice is 
freely available for academic use and can be accessible at 
https://github.com/zhangyimc/DeepSplice. 
We employ the following metrics: Area Under the ROC Curve (auROC), Area 
Under the Precision Recall Curve (auPRC), sensitivity, specificity, accuracy, F measure 
and 𝑄9. 𝑄9 is independent of the class distribution in the data set and is used to evaluate 
the classifier performance on splice site prediction [57]. 
 
24 
 
2.3 Experimental results 
We first applied our approach to a benchmark dataset HS3D [71] and compared the 
performance with other state-of-the-art approaches for donor and acceptor splice site 
classification. We then evaluated DeepSplice’s performance by classifying annotated 
splice junctions from GENCODE gene annotation data [59]. Deep Taylor decomposition 
[62] was then applied for further interpretation of base level contribution of flanking splice 
sequence. Finally, we applied DeepSplice to intropolis [36], a newly published splice 
junction database with 42,882,032 splice junctions derived from 21,504 samples. The 
detailed results are described below. 
 
2.3.1 DeepSplice outperforms state-of-the-art splice site prediction method 
We utilized HS3D [71] (Homo Sapiens Splice Sites Data set, 
http://www.sci.unisannio.it/docenti/rampone/), a popular benchmark for measuring the 
quality of splice site classification methods. HS3D includes introns, exons and splice site 
sequences extracted from GeneBank Rel. 123. The splice site sequences in HS3D are with 
the length of 140 nucleotides. There are 2796 (2880) true donor (acceptor) splice sites and 
271,937 (329,374) false donor (acceptor) splice sites which all contain conserved GT (AG) 
dinucleotides. We constructed the 1:10 data set, which contains all the true splice sites and 
27,960 (28,800) randomly selected false donor (acceptor) splice sites. Binary 
classifications were conducted to identify the actual splice sites on donor and acceptor 
splice site data separately. 
DeepSplice was trained on donor and acceptor splice site sequences separately in 
order to compare with state-of-the-art approaches of splice site classification. The exact 
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same number of training and testing splice site sequences from HS3D were used for all 
approaches. Table 2.1 summarizes the classification accuracies on the 1:10 data set by 10-
fold cross-validation. To measure the quality of the classification results, we employed 
sensitivity, specificity, and 𝑄9 which is the global accuracy measure calculated from both 
sensitivity and specificity scores. Since the published splice site classification methods do 
not provide public tools for training and testing, the results of SVM+B [54], MM1-SVM 
[50], DM-SVM [55], MEM [56] and LVMM2 [57] were obtained from [55, 57]. As shown 
in Table 2.1, DeepSplice outperforms other methods in both sensitivity and specificity for 
both donor and acceptor splice site classification. For donor splice sites, there is a 95% 
likelihood that the confidence interval [0.0581, 0.0633] covers the true classification error 
of DeepSplice on the testing data. For acceptor splice sites, there is a 95% likelihood that 
the confidence interval [0.0814, 0.0872] covers the true classification error of DeepSplice 
on the testing data. 
 
Table 2.1  Evaluation of DeepSplice and state-of-the-art approaches for donor (acceptor) 
site classification on HS3D data set 
 Donor Acceptor 
 Sensitivity Specificity 𝑄9 Sensitivity Specificity 𝑄9 
LS-GKM 0.8679 0.8516 0.8595 0.8403 0.8319 0.8361 
SVM+B 0.9406 0.9067 0.9212 0.9066 0.8797 0.8920 
MM1-SVM 0.9256 0.9244 0.9247 0.8993 0.8869 0.8926 
DM-SVM 0.9469 0.9339 0.9399 0.9215 0.9073 0.9136 
MEM 0.9324 0.9275 0.9295 0.9153 0.8843 0.8978 
LVMM2 0.9424 0.9242 0.9323 0.9122 0.8970 0.9039 
DeepSplice 0.9571 0.9376 0.9465 0.9337 0.9139 0.9232 
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To deduce the most suitable architecture for learning the patterns in splice 
site/junction sequences, we then compared DeepSplice against two other prominent types 
of neural networks, multilayer perceptron network and long short-term memory network, 
in terms of classifying HS3D data set by 10-fold cross-validation. As shown in Figure 2.4, 
DeepSplice with convolutional neural network exceeds the other architectures, achieving 
an auROC score of 0.983 (0.974) on donor (acceptor) splice site classification and an 
auPRC score of 0.863 (0.800) on donor (acceptor) splice site classification. LSTM 
achieved an auROC score of 0.960 (0.942) on donor (acceptor) splice site classification 
and an auPRC score of 0.803 (0.721) on donor (acceptor) splice site classification. MLP 
achieved an auROC score of 0.931 (0.914) on donor (acceptor) splice site classification 
and an auPRC score of 0.650 (0.559) on donor (acceptor) splice site classification. In 
general, convolutional neural network is a well-studied architecture, which outperforms 
other deep learning architectures in almost all kinds of applications currently [72]. Even 
for speech recognition, convolutional neural networks recently beat recurrent neural 
networks. In our application, convolutional layers efficiently learned the complex 
information of nucleotide neighborhoods.  
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Figure 2.4  The ROC curves of DeepSplice, multilayer perceptron network (MLP) and long 
short-term memory network (LSTM) for donor (acceptor) splice site classification on the 
HS3D data set by 10-fold cross-validation. DeepSplice with convolutional neural network 
exceeds the other deep learning architectures, achieving an auROC score of 0.983 (0.974) 
on donor (acceptor) splice site classification. 
 
2.3.2 DeepSplice predicts newly annotated splice junctions with high accuracy 
Next, we evaluated the accuracy of DeepSplice in terms of splice junction 
classification. To achieve this, we trained DeepSplice using splice junctions extracted from 
the GENCODE annotation version 3c, and then tested the model on newly annotated splice 
junctions in the GENCODE annotation version 19. All GENCODE splice junctions used 
for training and testing are experimental validated by RT-PCR amplification. The training 
set contains 521,512 splice junctions, and the testing set contains 106,786 splice junctions. 
In both training and testing sets, half of the splice junctions are annotated, and the rest are 
false splice junctions randomly sampled from human reference genome (GRCh37/hg19). 
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We trained the first model by feeding the 521,512 training splice junction sequences 
to DeepSplice for a binary classification, splice junctions or not. In the meantime, we 
trained two other models separately by feeding the donor (acceptor) splice site sequences 
extracted from the 521,512 training splice junction sequences to DeepSplice for a binary 
classification, donor (acceptor) splice sites or not. This experiment was designed to 
determine whether making use of paired combinational information of donor and acceptor 
splice sites from a splice junction, instead of classifying donor or acceptor splice site 
individually, would ameliorate the quality of splice junction classification. In the first mode 
(Splice Junction Mode), the input splice junction sequences were with the length of 120 
nucleotides, reflecting 30 nucleotides of upstream and downstream nucleotides for both 
donor and acceptor splice site. In the second mode (Donor+Acceptor Site Mode), the input 
splice junction sequences were split into two substrings with the length of 60 nucleotides 
and then fed to donor (acceptor) splice site classification model separately. For the second 
mode, we defined that the probability of a splice junction being classified as positive is the 
product of the probability of its donor splice site being classified as positive and the 
probability of its acceptor splice site being classified as positive, considering the two splice 
site classification events are statistically independent [73]. Figure 2.5 shows the ROC 
curves of the two modes. Splice Junction Mode achieved an auPRC score of 0.990, 0.987 
for Donor+Acceptor Site Mode. Table 2.2 summarizes sensitivity, specificity, accuracy, 
and F1 score on the 106,786 testing splice junction sequences. Donor+Acceptor Site Mode 
acquires a higher specificity; however, Splice Junction Mode significantly outperforms 
Donor+Acceptor Site Mode in terms of sensitivity, accuracy, F1 score, auROC score, and 
auPRC score with substantially higher scores. In total, Splice Junction Mode predicted 
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50,340 out of 53,393 newly annotated splice junctions, which covered 9,806 genes, 98.01% 
of all newly annotated genes. Donor+Acceptor Site Mode detected 39,067 splice junctions 
from 9,185 genes. There is a 95% likelihood that the confidence interval [0.0432, 0.0456] 
covers the true classification error of DeepSplice on the testing splice junctions. These 
results indicate that the proposal splice junction classification in DeepSplice achieves high 
accuracy in identifying novel splice junctions in large data sets than conventional splice 
site classification.  
 
 
 
Figure 2.5  The ROC curves of DeepSplice Splice Junction Mode and Donor+Acceptor 
Site Mode for splice junction classification on the GENCODE data set. DeepSplice Splice 
Junction Mode achieves a higher auROC score of 0.989. 
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Table 2.2  Classification performance evaluation of different DeepSplice modes on 
GENCODE data set 
 
2.3.3 Interpretation of sequence features captured by DeepSplice 
There are highly conserved segments on splice junctions between exons and introns 
which help in the prediction of splice junctions by computational methods and decipher 
biological signals of splice junctions. We next further interpret which nucleotides 
contribute to the splicing process. This is achieved by the quantification of the contribution 
of nucleotides in splice junction sequences to the classification process using deep Taylor 
decomposition [62].  
DeepSplice employs convolutional neural network with two convolutional layers. 
In the convolutional layer, we defined filters with a shape of 3x1, which means filters scan 
the input sequence with a window size of 3 to learn the information of nucleotide 
neighborhoods. DeepSplice fundamentally is not using a single base but rather 3-mers or 
subsequences of length 3 as its features. Then deep Taylor decomposition runs a backward 
pass on the convolutional neural network to sign contributions. The contribution score of 
each single base in DeepSplice reflects the aggregated importance of the three 3-mers it 
belongs to. We first used deep Taylor decomposition to decompose cross-validation results 
of the HS3D dataset in terms of input splice site sequences. For nucleotides in the testing 
splice site sequences, scores were assigned to present their contribution. We obtained a 
graphical representation from which it is possible to judge which region in the splice site 
  Sensitivity Specificity Accuracy F1 score 
Splice site 
classification 
Donor 0.917 0.897 0.907 0.908 
Acceptor 0.873 0.913 0.893 0.891 
Splice 
junction 
classification 
Splice Junction Mode 0.943 0.968 0.956 0.955 
Donor+Acceptor Site 
Mode 
0.732 0.997 0.864 0.844 
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sequences is of importance. Figure 2.6 shows the contribution of nucleotides to the final 
decision function of DeepSplice. In general, intron sequences carry more discriminative 
information than exon sequences in this analysis. We then applied deep Taylor 
decomposition to the results of splice junction classification with the GENCODE data set. 
Figure 2.7 shows the contribution distribution of nucleotides in the testing splice junction 
sequences. Regions of increased importance in splice junction classification are consistent 
with the result from splice site classification. 
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Figure 2.6  Visualization of the contribution of nucleotides in the flanking splice sequences 
to the final decision function of DeepSplice on the HS3D dataset for donor (acceptor) site 
classification. For both donor and acceptor site classifiers, intronic bases close to GT-AG 
di-nucleotides achieve the most importance in the classifiers. In general, intron sequences 
carry more discriminative information than exon sequences. 
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Figure 2.7  Visualization of the contribution of nucleotides in the flanking splice sequences 
to the final decision function of DeepSplice on the GENCODE dataset for splice junction 
classification. The nucleotides in the proximity of a splice junction have the highest impact 
on the classification outcome. As observed in the splice site classifiers, the contribution 
distribution of nucleotides in the flanking splice sequences indicates that intron nucleotides 
carry more discriminative information than exon nucleotides. 
 
2.3.4 DeepSplice classification of intropolis 
The intropolis v1 database [36] contains a large number of putative junctions found 
across 21,504 human RNA-seq samples in the Sequence Read Archive (SRA) from spliced 
read alignments to hg19 with Rail-RNA [37]. There are 42,882,032 putative splice 
junctions in total, including 18,856,578 canonical splice junctions containing flanking 
string GT-AG, 24,025,454 semi-canonical splice junctions containing flanking string AT-
AC or GC-AG [74], and no non-canonical splice junctions which are not allowed by Rail-
RNA. Table 2.3 lists the number of splice junctions in each category separated by the 
number of reoccurrence in samples and total read support across all samples in four scales: 
(a) equal to 1 {1}, (b) more than 1 and no greater than 10 (1, 10], (c) more than 10 and no 
greater than 1000 (10, 1000] and (d) more than 1000 (1000, +∞). As listed in Table 2.3, for 
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our analysis, we only retain splice junctions in intropolis that are supported by more than 
one sample, followed by the filtering of false splice junction sequences due to repetitive 
sequences. After this pre-processing, 5,277,046 splice junctions were left for further 
classification. 
 
Table 2.3  Distribution of splice junctions from intropolis given the reoccurrence in 
samples and total read support 
Splice junction 
number 
Reoccurrence in samples 
{1} (1, 10] (10, 1000] (1000, +∞) 
T
o
ta
l 
re
a
d
s {1} 23M - - - 
(1, 10] 3,331K 11M - - 
(10, 1000] 91K 936K 3,301K - 
(1000, +∞) 38 187 124K 305K 
  “M” stands for “million”. 
  “K” stands for “thousand”. 
 
The DeepSplice model was trained on 812,967 splice junctions including (1) 
291,030 annotated splice junctions from GENCODE annotation version 19, (2) 271,937 
false splice junctions generated from the HS3D data set, and (3) 250,000 randomly selected 
semi-canonical splice junctions with only one read support from intropolis. Overall, 
DeepSplice classified 3,063,698 splice junctions as positive. Figure 2.8 (a) lists the 
proportions of positive canonical splice junctions, positive semi-canonical splice junctions 
and negatives from the classification results at different levels of average read support per 
sample. Splice junctions with average read support per sample more than 15 achieve a 
positive rate around 88%. In contrast, for splice junctions with average read support per 
sample no more than 1, only 36% are identified as positives. There is a significant rise in 
the probability to obtain a positive splice junction with the increase of the average read 
35 
 
support per sample. Around 99% positive splice junctions contain the canonical flanking 
string. Figure 2.8 (b) illustrates the proportions of positive semi-canonical and canonical 
splice junctions cumulatively with the increase of the average read support per sample. 
To further clarify characteristics of the positives, we categorized splice junctions in 
intropolis based on annotated splice sites in GENCODE annotation: (1) splice junctions 
with both splice sites annotated, (2) splice junctions with the donor splice site annotated, 
(3) splice junctions with the acceptor splice site annotated, and (4) splice junctions with 
neither the donor nor acceptor splice sites annotated. Figure 2.9 (a) shows the discrete 
proportions of negatives and positive splice junctions in each category above, given the 
average read support per sample. Results indicate that 97% of splice junctions with both 
sites annotated are classified as positives, while only 39% with both sites being novel are 
positive. Splice junctions connecting annotated splice sites also tend to be associated with 
higher read coverage. Figure 2.9 (b) illustrates the proportions of positive splice junctions 
in each category cumulatively with the increase of the average read support per sample. 
Figure 2.10 shows positive splice junctions in intropolis near known protein-coding 
junctions show a periodic pattern, such that splice sites which maintain the coding frame 
of the exon are observed more often than those which disrupt frame. This observation 
recapitulates patterns seen in studies of noisy splicing [41]. 
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Figure 2.8  Positive splice junctions tend to have high read support and contain the 
canonical flanking string. (a) Discrete proportions of negatives, positive semi-canonical 
splice junctions and positive canonical splice junctions from the classification results, 
given the average read support per sample. Splice junctions with average read support per 
sample more than 15 achieve a positive rate of around 88%. In contrast, for splice junctions 
with average read support per sample no more than 1, only 36% are identified as positive. 
There is a significant rise in the probability to obtain a positive splice junction with the 
increase of the average read support per sample. Around 99% positive splice junctions 
contain the canonical flanking string. (b) Cumulative proportions of positive semi-
canonical and canonical splice junctions with the increase of the average read support per 
sample. 
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Figure 2.9  Positive splice junctions tend to have both donor and acceptor sites annotated. 
(a) Discrete proportions of negatives, positive splice junctions without annotated site, 
positive splice junctions with acceptor site annotated, positive splice junctions with donor 
site annotated and positive splice junctions with two sides annotated, given the average 
read support per sample. 97% of splice junctions with both sites annotated are classified as 
positives, while only 39% with both sites being novel are positive. Splice junctions 
connecting annotated splice sites also tend to be associated with higher read coverage. (b) 
Cumulative proportions of positive splice junctions in each category with the increase of 
the average read support per sample. 
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Figure 2.10  Splice sites which maintain the coding frame of the exon are observed more 
often than those which disrupt frame. Positive splice junctions in intropolis near known 
protein-coding junctions show a periodic pattern. For each donor (acceptor) site in the 
positive splice junctions, we calculated its distance to the nearest annotated donor 
(acceptor) site, and then counted the frequency for each position. The red points denote 
positions that are a multiple of three base pairs from the major splice form, and the black 
points those that are not. 
 
2.4 Summary 
Even though splice junctions with high read support and/or high reoccurrence are 
more likely to be classified as real, a significant portion of relatively low-expressed splice 
junctions also carry true splicing signals. DeepSplice does not rely on sequencing read 
support, frequency of occurrence, or sequencing read length derived from experimental 
RNA-seq data sets, thus can be applied as an independent evidence for splice junction 
validation. The accumulation of RNA-seq data especially in different cell types, tissues 
and disease conditions will further consolidate the cell type-specificity and tissue-
specificity of some of these junctions and their corresponding isoforms. DeepSplice may 
provide the first round of filtering of RNA-seq derived splice junctions for further structural 
validation, and studies that assess functional annotation of these splice junctions are 
warranted. DeepSplice could also extend its functionality to discriminate splice junctions 
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that are highly or lowly supported by gene expression evidence and try to figure out what 
sequence patterns associate to this difference in future. For each input candidate splice 
junction, DeepSplice outputs a probability of being true, and the probability can be used as 
an input feature to the studies for learning the tissue-regulated splicing code [75] and the 
splicing in human tissues with a wide range of known diseases [76]. 
It is also well known that splicing can be changed due to mutations around the 
splice sites. Future studies that use subject-specific genomic sequences instead of reference 
genome sequences may further improve the accuracy of the DeepSplice model and 
classification performance. Additionally, DeepSplice can be further extended to the 
prediction of non-canonical splicing [77] that existing annotation has not captured, 
including not only exonic but also splicing involving Alu elements, small exons, and 
recursive splicing. Besides the classification of linear junctions, the identification of non-
linear splice junctions, such as circRNA junctions will also expand the functionality of 
DeepSplice. 
Employing deep convolutional neural network, we develop DeepSplice, a model 
inferred from the sequences of annotated exon junctions that can then classify splice 
junctions derived from primary RNA-seq data, which can be applied to all species with 
sufficient transcript annotation to use as training data. Results demonstrate that DeepSplice 
outperforms the state-of-the-art splice site classification tools in terms of both classification 
accuracy and computational efficiency. Our findings further indicate that valuable 
information is present in the nucleotide sequence local to the splice junction, data that 
conventional splice site prediction techniques discard. Nucleotide representations learned 
from the input sequences are meaningful and improve accuracy. The major application of 
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DeepSplice is the classification of splice junctions rather than individual donor or acceptor 
sites. For learning on large datasets of putative splice junctions, DeepSplice is orders of 
magnitude faster than the best performing existing alternatives, which becomes 
increasingly common considering the tremendous amount of new RNA-seq data being 
generated. 
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CHAPTER 3. INFERRING TRANSCRIPTION FACTORS GOVERNING METABOLIC 
REPROGRAMMING WITH TFMETA 
Metabolic reprogramming is a hallmark of cancer. In cancer cells, transcription 
factors (TFs) govern metabolic reprogramming through abnormally increasing or 
decreasing the transcription rate of metabolic enzymes, which provides cancer cells growth 
advantages and concurrently leads to the altered metabolic phenotypes observed in many 
cancers. Consequently, targeting TFs that govern metabolic reprogramming can be highly 
effective for novel cancer therapeutics. In this chapter, we present TFmeta, a machine 
learning approach to uncover TFs that govern reprogramming of cancer metabolism. Our 
approach achieves state-of-the-art performance in reconstructing interactions between TFs 
and their target genes on public benchmark data sets. Leveraging TF binding profiles 
inferred from genome-wide ChIP-seq experiments and 150 RNA-seq samples from 75 
paired cancerous (CA) and non-cancerous (NC) human lung tissues, our approach 
predicted 19 key TFs that may be the major regulators of the gene expression changes of 
metabolic enzymes of the central metabolic pathway glycolysis, which may underlie the 
dysregulation of glycolysis in non-small-cell lung cancer patients. 
 
3.1 Introduction 
Metabolism is collection of predominantly enzyme-catalyzed biochemical 
transformations that are needed for maintenance, growth and survival of an organism. For 
nearly a century, scientists have documented profound metabolic changes that occur in 
tumors [78]. Oncogenes and tumor suppressors are well-established regulators of 
metabolism, and dysregulated expression as well as mutations can lead to the altered 
metabolic phenotypes observed in many cancers [79, 80]. A high proportion of oncogenes 
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and tumor suppressor genes encode transcription factors (TFs) [81]. Most oncogenic 
pathways converge on sets of TFs that ultimately control gene expression patterns resulting 
in tumor formation and progression as well as metastasis [82]. Deregulated expression, 
activation or inactivation of TFs play critical roles in tumorigenesis. In cancer cells, TFs 
govern metabolic reprogramming by controlling the expression patterns of metabolic 
enzymes. For example, the transcription factor MYC is frequently overexpressed in human 
cancers and regulates the expression of many metabolic enzymes. In carcinomas, MYC 
drives increased Gln uptake and conversion to Glu by upregulating glutamine transporters 
and inducing the expression of metabolic enzyme GLS at the mRNA and protein level, 
leading to increased anaplerotic input via glutaminolysis into the Krebs cycle and increased 
Gln incorporation into lactate [79, 83, 84]. 
Comprehensive characterization of TF-metabolic enzyme interactions in cancer 
cells can help uncover potential TFs governing cancer metabolic reprogramming and 
prioritize targets for novel cancer therapeutics. Reconstructing interactions between TFs 
and their target genes from transcriptomic data is a long-standing and well-studied 
challenge in molecular and computational biology. Some interaction reconstruction 
methods [85-88] exploiting co-expression in gene expression patterns have successfully 
identified the interactions in the gene pairs whose expression vary sufficiently and correlate 
globally across a large set of samples. Other methods [89, 90] take advantage of differential 
gene expression to predict interactions between each TF and all the genes that are 
differentially expressed when the TF is deleted, overexpressed or perturbed. These 
methods, however, have at least two major drawbacks for reconstructing TF-target gene 
interactions. First, a fundamental assumption of current interaction reconstruction methods 
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using transcriptomic data is that mRNA levels of TFs and their target genes are strongly 
correlated; however, this assumption may not be true for all the data sets, especially for 
those containing complex TF-target gene interactions. The Dialogue on Reverse 
Engineering Assessment and Methods (DREAM) project performed an assessment of 35 
TF-target gene interaction reconstruction methods on both synthetic and real 
transcriptomic data sets [85]. The competing methods achieved an average AUROC score 
of 0.69 on the synthetic data set, but 0.55 on the real data sets. The poor performance on 
the real data sets was due to the low correlation at the mRNA level in the data, which would 
suggest that reliable reconstruction of complex TF-target gene interactions requires 
additional inputs besides transcriptomic data, for example, TF binding profiles. Second, 
current interaction reconstruction methods disregard the valuable pairing information of 
the samples in transcriptomic data, treating each input gene expression profile 
independently in their inference models. For cancer patients’ transcriptomic data, pairwise 
comparisons of gene expression profiles between matched cancerous (CA) and non-
cancerous (NC) samples of the same patient should circumvent the interferences from 
genetic and physiological variations, eliminating the prediction of false TF-target gene 
interactions caused by the variations. 
Here, we developed TFmeta [91], a machine learning method for the reverse 
engineering of TF-metabolic enzyme interactions that pinpoint TFs governing cancer 
metabolic reprogramming. TFmeta integrates transcriptomic data and TF binding profiles 
inferred from genome-wide ChIP-seq experiments, to learn non-linear interactions between 
TFs and their targets. Using a gold standard data set, namely DREAM5 network inference 
challenge [85] data, we demonstrate that TFmeta outperformed the winner of the challenge 
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in reconstructing TF-target gene interactions. Taking 150 RNA-seq samples from 75 paired 
CA and NC human lung tissues and TF binding profiles as input, TFmeta predicted a set 
of key TFs that may control the transcription rate of metabolic enzymes in the central 
metabolic pathway glycolysis, which may cause the observed metabolic reprogramming in 
glycolysis pathway in non-small-cell lung cancer patients [91]. 
 
3.2 TFmeta method 
 
3.2.1 RNA-seq analysis 
We sequenced 150 RNA-seq samples from 75 paired CA and NC human lung 
tissues under IRB approval from the University of Kentucky. All patient information was 
de-identified and adhered to HIPPA guidelines. 100 bp paired-end reads were generated 
by Illumina HiSeq 2000 sequencer. RNA-seq reads were mapped to the human reference 
genome GRCh38, and gene expression values (TPM, transcripts per million) were 
estimated using RSEM package [92]. Gene expression profiles generated from RSEM were 
normalized and comparable between samples. Pairwise gene expression comparisons of 
CA and NA samples from the same patient were conducted through measuring the log2 
ratios of gene expression values between CA and matched NC samples. Based on the log2 
ratios, we maintained a master table for showing the regulation status of each gene in each 
individual patient. The regulation status of each gene was represented by a categorical 
variable that can take on one of the three possible values: upregulated, downregulated, and 
no change. Genes with the |log2| ratio greater than 0.8 were categorized as upregulated (or 
downregulated) genes, and the rest were genes with no expression change. The size of the 
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master table was 19,814 (number of genes) by 75 (number of patients). Using the gene 
expression log2 ratio of paired CA and NC tissue samples from the same patient should 
reduce the effects of individuality and the impact of tissue-specific genes and consequently, 
increase the accuracy of predicting clinical outcomes [93]. 
We then collected the detailed information of the major metabolic pathways in 
human, including glycolysis, the Krebs cycle, purine metabolism, and others from KEGG 
(Kyoto Encyclopedia of Genes and Genomes) pathway database [94]. The regulation status 
of metabolic enzymes involved in each metabolic pathways was extracted from the master 
regulation status table. According to the one-tailed one-proportion z-test (with a 
hypothesized proportion of 0.6667), we considered metabolic enzymes with consistent 
expression change (upregulated or downregulated) among at least 57 patients out of the 75 
patients as altered metabolic enzymes (p-value for 57 patients: p=0.0433<0.05). 
 
3.2.2 Transcription factor binding profiling 
We integrated TF binding profiles which were inferred from genome-wide ChIP-
seq experiments in four public databases, including ChEA [95], ENCODE [96], JASPAR 
[97], TRANSFAC [98]. We eventually accumulated 2,286,192 TF DNA binding activities, 
involving 493 TFs and 23,644 target genes. The minimum, median and maximum number 
of TFs binding to a target gene is 1, 104 and 279, and the minimum, median and maximum 
number of target genes for one TF is 4, 1853 and 21545, respectively. The total number of 
metabolic enzymes involved in the major metabolic pathways is 366. For each altered 
metabolic enzyme, we curated a list of TFs which bind to the transcription start site of that 
enzyme according to the TF DNA binding activities. 
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3.2.3 TF-metabolic enzyme interaction inference 
Problem Definition     We approached the problem of uncovering TFs that govern 
cancer metabolic reprogramming by measuring the interactions between the altered 
metabolic enzymes and TFs binding to the transcription start sites of them. Through RNA-
seq analysis, we identified 𝑀 altered metabolic enzymes with consistent expression change 
between CA and matched NC samples. We divided the problem of inferring TF-metabolic 
enzyme interactions involving 𝑀 enzymes into 𝑀 sub-problems. Each of these sub-
problems uncovered the TFs regulating one of the enzymes. We generated 𝑀 sub-tables 
from the master regulation status table, each of which contained the regulation status of 
one enzyme and TFs which bind to the transcription start site of that enzyme according to 
the TF DNA binding activities. In the sub-table, for enzyme 𝑚 with 𝑇𝑚 TFs binding to its 
transcription start site, every patient’s regulation status profile can be expressed as 
(x𝑛
𝑚, 𝑦𝑛
𝑚), where 𝑛 ∈ {1, … , 𝑁} is the index of each patient out of 𝑁 patients, and x𝑛
𝑚 is a 
tensor of 𝑇𝑚 TF regulation status, and 𝑦𝑛
𝑚 is the regulation status of enzyme 𝑚. 
Interaction Inference as a Feature Selection Problem     TFs and their target genes 
are known to interact in a dynamic and nonlinear manner [99]. We hypothesize that the 
regulation status of the enzyme 𝑚 is a function 𝑓𝑚 of the regulation status of the 𝑇𝑚 TFs, 
and the function 𝑓𝑚 only employs the regulation status of the TFs that are direct regulators 
of the enzyme 𝑚. Identifying those TFs whose regulation status is predictive of the 
regulation status of the enzyme 𝑚 can be considered as a feature selection problem, which 
is to rank the input features in the function 𝑓𝑚 based on their relevance for predicting the 
output in machine learning terminology. Considering a large amount of TFs as input 
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features relative to a small set of learning patient regulation status profiles and the nonlinear 
relationship between input TFs and the output enzyme, we proposed to use gradient 
boosted trees [100, 101] to find the function 𝑓𝑚 and rank the input TFs by their relevance. 
Gradient tree boosting is a scalable and highly effective machine learning algorithm, which 
works well in reliably extracting relevant features and identifying non-linear feature 
interactions. 
Gradient Boosted Tree-based Model     For each sub-problem, we fitted a multi-
class classification model (𝑓𝑚) to predict the regulation status (upregulated, downregulated, 
no change) of the enzyme 𝑚 based on the combined regulation status of the 𝑇𝑚 TFs. 
Gradient boosted trees were employed to find the function 𝑓𝑚 which minimizes the multi-
class classification error rate which is calculated as the number of wrong predictions 
divided by the number of all predictions. To achieve this goal, classification and regression 
tree (also known as CART) recursively partitions the 𝑁 patients into smaller disjoint sets 
based on the input regulation status of TFs, aiming at minimizing the number of wrong 
predictions of the output enzyme regulation status in the resulting subsets. Classification 
and regression tree uses the tree structure to represent the recursive partition, and each of 
the leaves in the tree represents a cell of partition. The basic idea of tree boosting is to build 
additive models through classification and regression trees. Let 𝑏𝑚,𝑘(x𝑛
𝑚) be a 
classification and regression tree in mth sub-problem, which works as the base learner. In 
tree boosting, we built a model that is the sum of base learners as: 
𝑓𝑚(x𝑛
𝑚) = ∑ 𝑏𝑚,𝑘(x𝑛
𝑚)
𝐾
𝑘=1
, 
where 𝑘 ∈ {1, … , 𝐾} is the index of each base learner out of 𝐾 base learners. The target 
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additive model was built in a forward stagewise fashion. Namely, it started with the simple 
function 𝑓𝑚,0(x𝑛
𝑚) = 0, then iteratively adds base learners to minimize the multi-class 
classification error rate of 𝑓𝑚,𝑘−1(x𝑛
𝑚) + 𝑏𝑚,𝑘(x𝑛
𝑚). Gradient Boosting attempts to solve 
this minimization problem numerically via steepest descent. By iteratively shifting the 
focus towards problematic observations that were difficult to predict, the performance of 
the classification and regression tree is very much boosted. 
Feature Importance Measure: TF Ranking     A benefit of using CART-based 
methods is that after the trees are constructed, it is relatively straightforward to retrieve 
estimates of feature importance that allow ranking the input features according to their 
relevance for predicting the output. The importance is calculated for a single classification 
and regression tree by the amount that each attribute split point reduces the Gini impurity, 
weighted by the number of observations the node is responsible for. The feature importance 
scores are then averaged across all the classification and regression trees within the model. 
In this application, every CART-based sub-model solving one sub-problem yields a 
separate ranking of TFs as potential regulators of a target enzyme 𝑚 along with importance 
scores 𝐼𝑚,𝑡𝑚  for 𝑡𝑚 ∈ {1, … , 𝑇𝑚}. 
TF-metabolic enzyme Map     Our primary goal is ultimately using this approach 
to find a relatively small number of robust target TFs based on multiple lines of evidence. 
We considered a variety of strategies to select an appropriate threshold on the TF ranking 
in each sub-model. For instance, we could apply an independent threshold for each sub-
model, or we could use a uniform threshold across all sub-models. We found that optimal 
performance was obtained when we applied an overall threshold on the combined TF 
ranking. To combine the separate rankings of TFs in sub-models, we performed the 
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Wilcoxon signed-rank test on every pair of TFs to compare their ranks, which tested 
whether the ranks of one TF from all sub-models were significantly higher (or lower) than 
those of the other TF. Based on the test decisions of comparing all pairs of TFs, the orders 
of TFs were eventually determined to generate the combined ranking. Through evaluating 
the number of output TFs and their biological significance, we considered TFs in the top 
5% of the combined ranking as robust targets. The interactions between the predicted TFs 
and their target enzymes were then displayed in a TF-metabolic enzyme map. The overall 
workflow of TF-metabolic enzyme interaction inference is shown in Figure 3.1. 
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Figure 3.1  Overview of TF-metabolic enzyme interaction inference workflow. We divided 
the problem of inferring TF-metabolic enzyme interactions involving 𝑀 enzymes into 𝑀 
sub-problems. In each sub-problem, taking the regulation status table of one enzyme and 
TFs binding to its transcription start site as input, we utilized gradient boosted trees to 
identify those TFs whose regulation status is predictive of the regulation status of the 
enzyme. This learning process was repeated on all the 𝑀 enzymes. The predicted 
interactions between TFs and enzymes were then displayed in the TF-metabolic enzyme 
map as output. 
 
3.2.4 Implementation 
TFmeta was implemented using scikit-learn library (version 0.19.1) [102] and 
XGBoost library (version 0.7) [101] in Python (version 2.7.13) as task parallelized 
program. TFmeta [91] is freely available for academic use and can be accessible at 
https://github.com/zhangyimc/TFmeta. 
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3.3 Experimental results 
 
3.3.1 Benchmarking TFmeta with DREAM5 Network Inference Challenge data sets 
We utilized the data sets in Dialogue on Reverse Engineering Assessment and 
Methods (DREAM) 5 network inference challenge [85]. The DREAM project is a 
framework to enable an assessment of computational methods through standardized 
performance metrics and common benchmarks. DREAM5 challenge performed a 
comprehensive blind assessment of 35 TF-target gene interaction inference methods on 
Escherichia coli, Staphylococcus aureus, Saccharomyces cerevisiae and in silico 
microarray data. Table 3.1 summarizes the number of TFs, the number of genes, and the 
number of microarray chips for each network. DREAM5 challenge organizer claimed that 
Staphylococcus aureus data was not used for the final evaluation for the lack of a 
sufficiently large set of experimentally validated interactions. Each microarray data set is 
represented as a 𝑚 ∗ 𝑛 gene expression matrix, where 𝑚 is the total number of genes 
including both TFs and target genes, and 𝑛 is the total number of microarray measurements. 
Based on descriptions provided by participants, DREAM5 challenge classified the 35 
competing methods into six distinct categories: regression, mutual information, correlation, 
Bayesian networks, meta (methods that combine several different approaches) and others 
(methods that do not belong to any of the previous categories). 
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Table 3.1  Summary of DREAM5 Challenge Data Sets 
Network 
Number 
of TFs 
Number 
of genes 
Number of 
microarray chips 
In silico 195 1643 805 
S.aureus 99 2810 160 
E. coli 334 4511 805 
S. cerevisiae 333 5950 536 
 
TFmeta was trained and tested on the same benchmark data sets used by the 35 
competing methods. Since the input data is numerical, the gene expression values 
generated from microarray chips, the functionality of classification and regression trees 
(CART) in TFmeta was shifted from classification to regression. In DREAM5 challenge, 
standardized performance metrics were provided to evaluate the performance of different 
methods. An overall score was used to summarize the performance across the three 
networks, which is a comprehensive assessment on both the area under the precision-recall 
(AUPR) and receiver operating characteristic (AUROC) curves. We applied the same 
metrics used by the 35 competing methods to TFmeta. Figure 3.2 (a) shows the overall 
scores for TFmeta and the 35 competing methods. The winner of DREAM5 challenge, 
GENIE3 [88], achieved an overall score of 40.279. The overall score of TFmeta is 69.031, 
which outperforms the winner of DREAM5 challenge. 
Transcription-factor perturbation experiments can be applied to validate the 
biological significance of the TFs predicted by computational methods. However, the usage 
of transcription-factor perturbation experiments is limited by their high cost and strong 
dependence on cellular type and context. Though TF-target gene interaction inference 
methods reconstruct gene regulatory networks with a large set of regulatory interactions, 
the number of TFs chosen for further experimental validation is always limited, and it is 
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highly likely that only the top predicted interactions will be selected for further validation. 
We then evaluated the accuracy of the top interactions predicted by GENIE3 and TFmeta. 
As shown in Figure 3.2 (b), TFmeta consistently achieved a higher accuracy than GENIE3 
for the top predictions on in silico data set, indicating that the most significant interactions 
predicted by TFmeta are more likely to be true interactions than those by GENIE3. We 
further compared TFmeta with GENIE3 in terms of computational efficiency. Figure 3.2 
(c) illustrates the total CPU running time of GENIE3 and TFmeta for reconstructing the 
testing gene regulatory networks. It took GENIE3 761.58 hours to finish the entire 
reconstruction job, but only 6.03 hours for TFmeta. TFmeta is orders of magnitude faster 
than GENIE3. 
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Figure 3.2  Performance evaluation of DREAM5 challenge data sets. (a) demonstrates the 
overall scores for TFmeta and the 35 competing methods. The winner of DREAM5 
challenge, GENIE3, achieved an overall score of 40.279. The overall score of TFmeta is 
69.031. (b) illustrates the accuracy of the top interactions predicted by GENIE3 and 
TFmeta. TFmeta consistently achieved a higher accuracy than GENIE3. (c) shows the total 
CPU running time of GENIE3 and TFmeta on the testing datasets. TFmeta is orders of 
magnitude faster than GENIE3. 
 
3.3.2 Prediction of TFs governing the dysregulation of glycolysis in NSCLC patients 
All parts of the body require energy to maintain non-equilibrium cellular states and 
perform work, and this energy is derived from consumption and oxidation of external 
nutrients. Typically, all food is broken down into smaller parts and coupled to the 
production of the main energy intermediate, ATP. ATP provides a uniformly usable store 
of biochemical energy that can be used to drive endergonic cellular reactions. The process 
of the breakdown of glucose, termed glycolysis, occurs in the cytoplasm of mammalian 
cells [103]. Since the early twentieth century, abnormalities of glycolysis in cancer cells 
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have been observed [104]. Marked progress has been made in understanding the molecular 
mechanisms leading to constitutive upregulation of glycolysis in tumor cells. Many 
glycolytic enzymes are often overexpressed in cancer cells. For example, 
phosphofructokinase-1 (PFK1) has been identified to be upregulated in types of breast 
cancer [105]. Another well-known classic glycolytic enzyme, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) is also implicated in cancer. Overexpression of GAPDH is 
considered an important feature of numerous types of cancer [103]. GAPDH has been 
proposed as a promising target for the treatment of carcinomas [106]. Both MYC and 
HIF1a are known to upregulate expression of most of the glycolytic enzymes in cancers 
[107]. These results indicate that uncovering TFs that govern the abnormal expression 
patterns of these glycolysis and/or glycolytic enzymes in tumor cells may underlie the 
abnormalities of glycolysis, which could be highly effective for the treatment of different 
types of cancer. 
We acquired 150 RNA-seq samples from 75 paired CA and NC human lung tissues. 
Through pairwise gene expression comparisons of CA and NA samples from the same 
patient, we identified 14 altered glycolytic enzymes with consistent expression changes. 
ENO1, ENO2, GAPDH, GPI, LDHA, PFKP, PKM, and TPI1 were upregulated, whereas 
ACSS2, ADH1B, ALDH2, ALDH3B1, FBP1, and HK3 were downregulated. Using a 
network editor, Omix [108], we visualized the patient-specific regulation status of part of 
glycolytic enzymes in four selected patients (UK022, UK059, UK084, and UK085) in the 
context of glycolysis pathway extracted from KEGG [94] pathway database, as shown in 
Figure 3.3. Each pie chart in Figure 3.3 depicts the regulation status of one enzyme in one 
patient. The pie chart with a larger slice of red (white) indicates the upregulation 
56 
 
(downregulation) of the enzyme. Though they are all non-small-cell lung cancer patients, 
individual differences in the regulation status of some enzymes can be observed. In the 
meanwhile, some well-known glycolytic enzyme, like PFKP, GAPDH, and PKM, are 
consistently upregulated in the four patients. This pairwise comparison analysis and 
patient-specific visualization eliminated the interferences from genetic and physiological 
variations, and also characterized the difference and consistency in regulation status among 
the patients. 
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Figure 3.3  Visualization of the regulation status of part of glycolytic enzymes in the 
context of glycolysis pathway. We randomly selected four patients: UK022, UK059, 
UK084 and UK085 (from left to right). Each pie chart in the figure illustrates the regulation 
status of one enzyme in one patient. The pie chart with a larger slice of red (white) indicates 
the upregulation (downregulation) of the enzyme. Individual differences in the regulation 
status of some enzymes can be observed among the four patients. Meanwhile, some well-
known glycolytic enzymes, like PFKP, GAPDH, and PKM, are consistently upregulated 
in the four patients. In total, twelve (three) out of thirty-five enzymes shown in the figure 
are consistently upregulated (downregulated) in the four patients. Glycolytic enzymes are 
more likely to be overexpressed in cancer cells. 
 
For every altered glycolytic enzyme, we curated a list of TFs which bind to the 
transcription start site of that enzyme according. to the TF DNA binding activities inferred 
from ChIP-seq experiments. The average number of TFs selected for one enzyme is 134. 
We then fitted a gradient boosted tree-based classification model to predict the regulation 
status of each altered glycolytic enzyme based on the combined regulation status of the 
selected TFs. The optimal model configuration was achieved by extensive hyperparameter 
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search over various learning rate (0.001, 0.01, 0.1, and 1), maximum tree depth (1, 3, and 
5), and number of rounds for boosting (100, 200, 300, and 400). To evaluate the 
performance of models with different parameter settings, 10-fold cross-validation was 
used. Table 3.2 summarizes the average prediction accuracy of models varying parameter 
settings upon the 14 altered glycolytic enzymes. Based on this results, we used 0.01 as 
learning rate, 3 as maximum tree depth, and 300 as number of rounds for boosting in our 
model to save the computing time without loss of classification accuracy. 
 
Table 3.2  Performance evaluation of models with different parameter settings 
Learning rate 
Maximum 
tree depth 
Number of rounds 
for boosting 
Accuracy 
0.001 
3 300 
0.696 
0.01 0.723 
0.1 0.661 
1 0.634 
0.01 
1 
300 
0.714 
3 0.723 
5 0.723 
0.01 3 
100 0.679 
200 0.714 
300 0.723 
400 0.705 
 
The application of TFmeta allows us to narrow down to a list of key TFs as 
modulating the dysregulated expression of those altered glycolytic enzymes. Figure 3.4 
shows the TF-metabolic enzyme map predicted by TFmeta. In the map, the 14 altered 
glycolytic enzymes (red squares) and 19 predicted TFs (blue squares) are nodes, and an 
edge from one TF to one enzyme demonstrates that TF is predicted to regulate that enzyme, 
and all the edges are directed. Some predicted TFs and their interactions with glycolytic 
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enzymes in the map have already been supported by literature evidence. For example, 
transcription factor E2-alpha (TCF3) was identified as novel putative TF in lung cancer 
[109]. ETS Proto-Oncogene 1 (ETS1) was reported as a key TF involved in the metabolism 
of cancer cells, and ETS1 is particularly important in the metabolic shift towards glycolysis 
and anabolic means of energy production [110]. Enhancer of zeste homolog 2 (EZH2) 
promotes tumorigenesis and malignant progression in part by activating glycolysis. The 
mRNA expression of key enzymes involved in glycolysis in xenograft tumors was 
significantly increased in tumors derived from cells overexpressing EZH2, which suggests 
EZH2 overexpression leads to increases in glycolysis in vivo [111]. Forkhead box 
transcription factor-2 (FOXA2) was implicated as a suppressor of lung cancer, playing an 
important role in lipid and glucose metabolism in lung development using Foxa2+/– mice 
model [112]. Another well-known TF, MYC is a critical growth regulatory gene that is 
commonly overexpressed in a wide range of cancers. Overexpression of MYC leads to the 
upregulation of many glycolytic enzymes [113]. Zinc finger and BTB domain-containing 
protein 7A (ZBTB7A) acts as a tumor suppressor through the transcriptional repression of 
glycolysis, which directly binds to the promoter and represses the transcription of critical 
glycolytic enzymes, including GLUT3, PFKP, and PKM [114]. Krüppel-like factor 4 
(KLF4) represses the transcription of the glycolytic enzyme LDHA in pancreatic cancer 
[115]. We propose that these TFs should be prioritized for follow-up experiments, both to 
validate predicted target metabolic enzymes and to evaluate specific biological functions 
for each TF. We further visualized the regulation status of 8 well-known classic glycolytic 
enzymes and 2 predicted TFs, KLF4 (known as a tumor suppressor gene in lung cancer) 
and EZH2 (known as an oncogene), in the 75 patients, as shown in Figure 3.5. The 
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regulation status of EZH2 and the 8 enzymes are positively correlated, on the contrary, 
KLF4 is negatively correlated with the 8 enzymes in terms of regulation status. 
 
 
 
Figure 3.4  Visualization of the TF-metabolic enzyme map predicted by TFmeta. In the 
map, the 14 altered glycolytic enzymes (red squares) and 19 predicted TFs (blue squares) 
are nodes, and an edge from one TF to one enzyme demonstrates that TF is predicted to 
regulate that enzyme, and all the edges are directed. 
 
Thus, in this pilot study, we demonstrated the feasibility of using TFmeta for 
uncovering TFs that govern glycolytic reprogramming in non-small-cell lung cancer 
patients. This approach should be equally powerful for deciphering other metabolic 
reprogramming in cancer cells, thereby enabling more comprehensive characterization of 
cancer metabolism. 
61 
 
 
 
 
Figure 3.5  Heatmap of the regulation status of 8 well-known classic glycolytic enzymes 
and 2 predicted TFs, KLF4 and EZH2, in the 75 patients. The regulation status of EZH2 
and the 8 enzymes are positively correlated, on the contrary, KLF4 is negatively correlated 
with the 8 enzymes in terms of regulation status. EZH2 is known as an oncogene, and 
KLF4 is a tumor suppressor gene in lung cancer. 
 
3.3.3 Prediction of TFs governing other major metabolic pathways in NSCLC patients 
We further applied TFmeta to infer TFs that govern other major metabolic 
pathways in non-small-cell lung cancer patients. The Krebs cycle is a central metabolic 
hub that integrates carbohydrate, lipid, and amino acid metabolism. The pentose phosphate 
pathway (PPP) is an alternative route for glycolysis, yielding ribose 5-phosphate for 
nucleotide biosynthesis and NADPH for fatty acid biosynthesis and decomposition of 
peroxides [116]. Purine metabolism maintains cellular pools of adenylate and guanylate 
via synthesis and degradation of purine nucleotides. The top TFs predicted for each 
metabolic pathway are shown as follows: 
a) The Krebs cycle: ZBTB7A, MYC, SMARCB1, TAL1, TCF7L2; 
b) The pentose phosphate pathway: FOXA2, MYC, EGR1, TCF3, ZEB1; 
c) Purine metabolism: MYC, H2AFZ, EZH2, NFIC, ETS1, TCF3, BHLHE40, 
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CEBPB, STAT1, MAFK. 
 
3.4 Summary 
Metabolic reprogramming of cancer cells is recognized as one of the hallmarks of 
cancer. Tumors remarkably elevate the expression of the majority of metabolic enzymes, 
which play active roles in promoting cancer survival, metastasis, and invasion. One of the 
most common trends in anti-cancer metabolism therapies is to inhibit metabolic enzymes 
that are exclusively or mostly expressed or used in tumor cells. This therapeutic strategy 
would effectively eliminate tumors while minimizing damage to normal cells [117]. Thus, 
targeting TFs that control the transcription rate of those metabolic enzymes could be highly 
effective for novel cancer therapy. 
In this work, we develop TFmeta, a machine learning approach to uncover TFs 
governing cancer metabolic reprogramming and reconstruct their interactions with metabolic 
enzymes. We demonstrated that TFmeta achieved state-of-the-art performance in recovering 
TF-target gene interactions on public benchmark data sets. We applied our model to non-
small-cell lung cancer patients’ data sets to predict TFs modulating the dysregulation of 
glycolysis in lung cancer, leveraging the pairing information of the samples and TF DNA 
binding activities that conventional approaches discard. Eventually, we predicted a list of key 
TFs that may motivate the upregulation of glycolysis observed in tumor cells, some of which 
have been supported by literature evidence, and some of which were predicted as novel 
putative TFs in lung cancer. Our model can also be easily deployed to uncover TFs governing 
other metabolic pathways, in addition to glycolysis. 
Based on our results, we found the majority of metabolic enzymes have interactions 
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with more than one TFs. TFs are known to have to work together to achieve needed 
specificity in both DNA binding and effector function [118]. In our current model, the 
analysis of TF-TF relationships is generally lacking. TFmeta could extend its functionality 
to evaluate the associations of TFs in future. 
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CHAPTER 4. WHOLE MAMMOGRAM IMAGE CLASSIFICATION WITH CONVOLUTIONAL 
NEURAL NETWORKS 
Due to the high variability in tumor morphology and the low signal-to-noise ratio 
inherent to mammography, manual classification of mammogram and tomosynthesis yields 
a significant number of patients being called back, and subsequent large number of biopsies 
performed to reduce the risk of missing cancer. The convolutional neural network (CNN) 
is a popular deep learning construct used in image classification. This technique has 
achieved significant advancements in large-set image-classification challenges in recent 
years. In this study, we had obtained over 3000 high-quality original mammograms and 
tomosynthesis with approval from an institutional review board at the University of 
Kentucky. Different classifiers based on CNNs were built to classify both the 2D 
mammograms and 3D tomosynthesis, and each classifier was evaluated based on its 
performance relative to truth values generated by histology results from biopsy and two-
year negative mammogram follow-up confirmed by expert radiologists. Our results 
showed that CNN model we had built and optimized via data augmentation and transfer 
learning have a great potential for automatic breast cancer detection using mammograms 
and tomosynthesis. 
 
4.1 Introduction 
Breast cancer is the most common cancer in women. Approximately 40,000 breast 
cancer patients die each year in the U.S [119]. Early detection of cancer significantly 
reduces the death rate [120]. To find breast cancer in early stages, before patients exhibit 
symptoms, women are recommended to undergo a screening test, commonly a 
mammogram. Mammography entails exposing a patient’s breasts to low levels of X-ray 
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radiation. Breast cancer are identifiable from mammograms thanks to the different X-ray 
absorption rates of normal and abnormal tissues. Tumors can appear as masses, distortions 
or micro-calcifications on mammograms [121]. In patient with dense breast tissue, the 
tumor mass may overlap with the dense tissue, creating masking effect and making 
mammography less sensitive. Breast tomosynthesis is a newly emerging breast imaging 
technique first approved by the FDA in 2011. It takes multiple X-ray images at different 
angles; the images are then reconstructed to yield a video from which a radiologist can 
identify abnormalities. Compared to traditional mammograms, tomosynthesis provides 
more accurate results because tumors can be more easily distinguished from dense tissues 
using images taken from different angles [122]. Normally, mammograms and 
tomosynthesis were acquired in two standard orientations: Craniocaudal (CC) and Medial-
lateral-oblique (MLO) views during screening. Figure 4.1 shows an example of the CC and 
MLO views of mammogram of two breasts, and Figure 4.2 shows an example of the 
multiple slices of the right CC view of tomosynthesis from the same patient. 
 
 
 
Figure 4.1  Illustration of 2D mammogram (from left to right): right CC view, left CC view, 
right MLO, left MLO view. 
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Figure 4.2  Illustration of 3D tomosynthesis: multiple slices of right CC view. 
 
Screening mammography is the only imaging modality that has been proven to 
reduce breast cancer mortality [123]. However, mammography is also associated with high 
recall rates and high false-positive results [124]. With current practice, approximately 10% 
of all women screened for breast cancer are called back for additional work-ups, but only 
0.5% are diagnosed with breast cancer (that is, 5 cancer detected out of 1,000 women 
screened, or 5 out of the 100 women called back). The use of the new technology, 
tomosynthesis in conjunction with mammography, was showed to improve the accuracy of 
cancer detection [125]. However, manual classification by radiologists still incurs a high 
recall rate and requires years of experience on the part of the radiologist. This high recall 
rate results in an abundance of additional diagnostic tests, including biopsy, and thus 
contributes to increased health-care costs as well as unnecessary emotional turmoil for the 
patients themselves [121, 126, 127]. 
Deep learning with convolutional neural networks has emerged as one of the most 
powerful machine-learning tools in image classification, surpassing the accuracy of almost 
all other traditional classification methods and even human ability [128]. The convolutional 
process can simplify an image containing millions of pixels to a set of small feature maps, 
67 
 
thereby reducing the dimension of input data while retaining the most important differential 
features. The application of CNNs to classify mammograms is not entirely new. However, 
most of the work focus on the classification of small patches, referred to as region of 
interest (ROI) [129]. An ROI is the region that is likely to contain a tumor. This is typically 
carved out of the whole images based on either clinical information or automatic 
segmentation. Daniel Lévy et al. used deep CNNs on small patches of mammograms, 
achieving a maximum accuracy of 93% [130]. Neeraj Dhungel et al. built a deep learning 
based method that automatically segments the area of lesions and then classifies the 
mammogram. Their best results were 0.74 for whole image, 0.8 for whole image plus 
automatically detected small lession patches, and 0.91 for whole image plus manually 
segmented small patches in terms of auROC [131]. In general, the classification of 
mammograms using small abnormality patches affords reasonable performance but 
requires very extensive pre-processing work. 
An effective classification model for whole mammograms would offer multiple 
benefits, including (a) saving the work of annotating partial mammograms and its 
associated segmentation errors, (b) optimizing the use of contextual information 
surrounding tumors, (c) closely representing the real-world clinical practice, and (d) 
reducing the patient call-back rate, and thus the number of unnecessary tests conducted, 
without harming sensitivity. However, classification with whole images is much more 
challenging than with small patches due to the increased size and feature space. The best 
performance reported on whole mammography classification with CNN is 60.90% in terms 
of accuracy by Henry Zhou et al [132]. 
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In this work, we developed and evaluated a number of CNN models for whole-
mammography image classification [133]. We also present the first breast cancer 
classification model using 3D tomosynthesis data, a relatively new technology that is only 
available to 20% of major hospitals in the US. All images were collected at the Department 
of Radiology, University of Kentucky with an institutional review board approval (IRB17-
0011-P3K). Techniques including data augmentation [134] and transfer learning [135] are 
combined with CNN models to optimize the performance of the classifiers. 
 
4.2 Architecture overview 
Our approach employs deep convolutional neural networks to classify whole-
mammography images from both the 2D mammograms and 3D tomosynthesis data. The 
pipeline consists of three stages: data augmentation, transfer learning and CNNs. Ten 
different models in total were developed, optimized and compared through cross validation 
[136]. 
 
4.2.1 Data augmentation 
Generally, deep neural networks require training on a large number of training 
samples to perform well. However, biomedical datasets like ours contain a relatively small 
number of samples due to limited patient volume. Data augmentation is a method for 
increasing the size of input data by generating new data from the original input data. Many 
strategies exist for image data augmentation [5, 128]. This study employed a combination 
of reflection and rotation. For the 2D mammograms, each original image was flipped 
horizontally. The original and reflected images were then rotated by each of 90, 180, and 
69 
 
270 degrees. Each original image was thus augmented to eight images. For each 
tomosynthesis sample, the 3D image sequences as a whole were either horizontally flipped 
or not flipped, and then randomly rotated 0, 90, 180 or 270 degrees. Such data 
augmentation generates relevant training samples because tumors may present themselves 
in various orientations. 
The data augmentation can be performed either before the training or during 
training. Frontloading the augmentation process reduces the running time of the tests but 
requires 8 times more disk space to store all images. While this is applicable for 2D images, 
for the 3D tomosynthesis data, data augmentation was performed during the training phase 
to minimize storage usage. 
 
4.2.2 Transfer learning 
Transfer learning is the re-use of information obtained during the training phase of 
a previous project. In the field of image classification, the CNNs [128] trained in the course 
of successful projects are sometimes published for use by other researchers. Two popular 
transfer-learning methods involve (a) fine-tuning the parameters in certain layers of the 
trained CNN, or (b) using the trained CNN to calculate the feature maps of new types of 
data.  
Mammography data is different from natural image data due to its limited color 
distribution and structures. However, it can still leverage the basic image features in terms 
of edges and shapes that can be soundly detected by well-trained CNN models. This study 
utilizes AlexNet [128], trained with ImageNet [137]. Considering the fact that 
mammograms differ dramatically from the images in the ImageNet dataset, the trained 
70 
 
AlexNet was used only to obtain the feature maps. Each image in the augmented dataset 
was resized to 832*832, which resolution was chosen with the goal of retaining tumor pixel 
information. The ImageNet trained AlexNet was deployed to generate the feature maps for 
the resized images. AlexNet output the feature maps with the shape of 25*25*256. The 
feature maps were then used in the training of the following shallow CNNs. 
 
4.2.3 CNN architectures 
We have built different architectures of convolutional neural networks to classify 
the 2D mammograms and 3D tomosynthesis images. A general shallow CNN architecture 
is shown in Figure 4.3. Each convolution layer (Conv layer) includes convolution, batch 
normalization [138], leaky ReLU [139] and max pooling [128]. All CNNs used Max 
pooling with stride 2. The optimizer used is the Adam optimizer [65]. L2 regularization 
was introduced in the loss function to prevent overfitting [66]. Dropout was also included 
to improve the model performance [67]. We also adopted two top-performing CNN 
architectures, AlexNet [128] and ResNet50 [140], to classify the 2D whole mammograms. 
Additionally, we have built several models incorporating transfer learning with feature 
maps learned from AlexNet. Detailed mathematical description of each step is omitted in 
this paper as they are well established deep learning techniques. 
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Figure 4.3  Sample convolutional neural network architecture used in this study. Conv layer 
denotes the convolution, batch normalization, leaky ReLU and max pooling process. Conv 
layers are followed by fully connected layers (Fully conn) and output layer. 
 
The complete list of architectures is provided in Table 4.1. During the training 
phase, learning rate, dropout and L2 regularization beta were tuned with the range of 
0.0001 to 0.1, 0.25 to 1 and 0.00001 to 0.1 respectively. The learning rate decay rate of 
Adam optimizer was set to 0.985 based on the preliminary results. The batch size was set 
by two rules: (1) power of two and (2) largest data size can fit the 8 GB memory. 
 
Table 4.1  Detailed architectures of tested models for 2D mammogram and 3D 
tomosynthesis classification 
Architecture 
Transfer 
Learning 
Input Shape conv1 conv2 conv3 fc1 fc2 Output 
2D-A1 No 224*224*3 6@5*5 16@3*3 -- 1024 1024 2 
2D-A2 No 224*224*3 16@3*3 32@3*3 64@3*3 1024 1024 2 
AlexNet No 224*224*3 -- -- -- -- -- 2 
ResNet50 No 224*224*3 -- -- -- -- -- 2 
2D-T1-Alex Yes 25*25*256 256@1*1 -- -- 1024 -- 2 
2D-T2-Alex Yes 25*25*256 256@1*1 -- -- 1024 1024 2 
2D-T3-Alex Yes 25*25*256 256@1*1 -- -- 512 512 2 
3D-A1 No 128*128*16*3 16@3*3*3 32@3*3*3 64@3*3*3 1024 1024 2 
3D-T1-Alex Yes 25*25*16*256 32@3*3*3 -- -- 256 256 2 
3D-T2-Alex Yes 25*25*16*256 256@1*1*1 -- -- 256 256 2 
 
Imbalanced data represent a common problem in machine-learning projects [141]. 
If imbalances in the training data are not considered, the resulting model generally 
performs well on the larger class but poorly on the smaller class. The target dataset for this 
72 
 
study was classically imbalanced, with roughly 90% of samples representing negative 
diagnoses. To reduce the imbalance effect, the mini-batches [138] selected during the 
training phase were restricted to be balanced. During each training epoch, the training data 
were randomly split into m folds: 
m =
Npos
n/2
 
where Npos denotes the number of positive samples (smaller class) in the training set, and 
n is the batch size. In each iteration, all positive samples (n/2 samples) and n/2 randomly 
selected negative samples of 1-fold training data were fed to train the CNN. 
For the data input, 2D mammograms and their feature maps were read as three 
dimensional tensors with shape defined as length*width*channels. 3D tomosynthesis data 
and their feature maps were read as four dimensional tensors with shape defined as 
length*width*depth*channels. Here, depth denotes the number of frames of 3D 
tomosynthesis data, which may vary across tomosynthesis samples. To obtain a fixed input 
shape, an equal number of frames were selected for each sample. Selected frames were 
start from frame 0 and with equal interval in one tomosynthesis sample. In this study, the 
frame number was set to 16 to fit the hardware limitation. 
 
4.2.4 Implementation and performance evaluation 
The convolutional neural networks were implemented using TensorFlow [70]. All 
the tests were performed on a machine with two groups of four Nvidia GTX 1080 GPUs, 
each with 8 GB memory. 
To evaluate the performance of each prediction model, cross validation was used. 
The dataset was randomly partitioned into training and testing datasets. The training set 
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was used to train the model; the results of predictions made on the testing set were used to 
evaluate the performance of the model. The training-testing ratio used in all validation tests 
was 4:1. 
Receiver operating characteristic curve (ROC) [142] is plotted as the true-positive 
rate versus the false-positive rate at various thresholds. The area under the ROC curve, 
auROC is used to measure the performance of a binary classifier. Tradeoffs can be made 
based on ROC curves to select the most appropriate classification model. When testing the 
prediction models in this study, probability of all test samples in each class was calculated. 
Using each value in the probability set as the threshold, we can derive true-positive rates 
(TPRs) and false-positive rates (FPRs). These TPR-FPR data were then used to plot the 
ROC curve and calculate the auROC. 
 
4.3 Experimental results 
 
4.3.1 Data description 
High-quality mammogram data from the University of Kentucky Medical Center 
were obtained with institutional review board approval (IRB 17-0011-P3K). All 
mammography images were assessed by experienced radiologists. The dataset includes 
3,018 negative and 272 positive mammogram images. Each of the positive image contains 
at least one biopsy-proven malignant tumor. The negative images do not contain malignant 
tumors confirmed with at least 2- year negative mammogram follow-up assessed by 
radiologists, but may have benign masses approved by biopsy or established more than 2 -
year imaging stability. All exams in the dataset were taken in either CC or MLO view or 
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both. Negative images originated from 793 patients, most of which had 4 images taken: 
namely, CC and MLO views for both left and right breasts. Positive samples originated 
from 125 patients. Most positive patients have two images collected: CC and MLO views 
of the breast site with tumor. For each exam, both 2D mammogram and 3D tomosynthesis 
results were obtained. The 2D mammograms were provided in 12-bit DICOM format at 
3328*4096 resolution. The 3D tomosynthesis images were provided in 8-bit AVI format 
with a resolution of 768*1024.  Table 4.2 summarizes the dataset used in this study. All 
data were de-identified to protect the patients’ privacy. In order to save storage space and 
reduce the time of file I/O, the pixel array for each 2D mammogram DICOM file was saved 
as a 16-bit JPEG image. For each 3D tomosynthesis AVI file, all frames were processed to 
a set of 8-bit JPEG images for the same purpose. The total number of frames for each 3D 
tomosynthesis exam varies from 21 to 120. 
 
Table 4.2  2D mammogram and 3D tomosynthesis data used in this study 
View Negatives Positives 
RCC 758 77 
RMLO 759 73 
LCC 751 64 
LMLO 750 58 
Total 3018 272 
 
4.3.2 Effect of data augmentation 
Data augmentation increases the size of the training dataset 8-fold. It significantly 
improves the performance of almost every CNN architecture tested by roughly 0.1 auROC 
units. Figure 4.4 (A) and (B) depicts the training loss status of architecture 2D-T2 without 
and with data augmentation and Figure 4.4 (C) shows the associated ROC curves. The 
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auROC of the test with data augmentation is 0.73 comparing to 0.62 for the test without 
data augmentation. The training loss converged more smoothly with data augmentation 
than without. For this reason, all subsequent tests utilized the data augmentation strategy. 
 
 
 
Figure 4.4  Loss converge status of tests using data without (a) and with augmentation (b) 
and ROC curves of them (c). 
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4.3.3 2D mammogram classification 
We evaluated all CNN architectures on 2D mammography images listed in Table 
4.1. The loss converge status during the training phase of all those architectures were 
shown in Figure 4.5. The optimized parameter combination and results of the best shallow-
CNN model, the best classic-CNN model, and the best transfer-learning model for 2D 
mammograms are summarized in Table 4.3. 
While classic-CNN models such as AlexNet do generate competitive results, the 
best architecture seems to be the one leveraging transfer-learning where feature maps 
derived from ImageNet-trained AlexNet are used for training. For example, 2D-T2-Alex 
delivers the best auROC approaching 0.73. The result suggests that utilizing the pre-trained 
model can be more sensitive in detecting key elements such as edges and shapes within a 
mammogram image as well. However, due to inherent difference between mammogram 
image and natural images, further training with these features using even a shallow CNN 
still delivers better classification accuracy than using AlexNet alone. 
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Figure 4.5  Loss converge status of 2D mammogram classification models: (a) 2D-A1, (b) 
2D-A2, (c) AlexNet, (d) ResNet50, (e) 2D-T1-Alex, (f) 2D-T2-Alex, (g) 2D-T3-Alex. (h) 
illustrates the ROC curves of different models. 
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Table 4.3  Validation results and optimized parameter combination of 2D mammogram 
classification models 
Architecture 
Batch 
size 
Learning 
rate 
Dropout 
L2 regularization 
beta 
auROC 
2D-A1 128 0.1 0.5 0.001 0.5488 
2D-A2 128 0.1 1 0.001 0.6295 
AlexNet 128 0.0001 0.25 0.001 0.6749 
ResNet50 32 0.01 0.5 0.001 0.6239 
2D-T1-Alex 256 0.0001 0.5 0.0001 0.7234 
2D-T2-Alex 256 0.001 0.5 0.0001 0.7274 
2D-T3-Alex 256 0.001 0.5 0.01 0.7237 
 
4.3.4 3D tomosynthesis classification 
We also evaluated three architectures listed in Table 4.1 designed for 3D 
tomosynthesis images. Cross validation was used to test one model, 3D-A1, on 3D 
tomosynthesis data, and two models on 3D tomosynthesis feature maps derived from 
transfer learning. The loss converge status during the training phase of all 3D classification 
architectures were shown in Figure 4.6. The optimized parameters and auROCs for the 
three models are shown in Table 4.4. Based on the tests, 3D-T2-Alex exhibited the best 
performance on 3D tomosynthesis feature maps; similar to 2D images, transfer learning 
using ImageNet-trained AlexNet was able to improve the performance of 3D 
tomosynthesis classification models. 
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Figure 4.6  Loss converge status of 3D tomosynthesis classification models: (a) 3D-A1, (b) 
3D-T1-Alex, (c) 3D-T2-Alex. (d) illustrates the ROC curves of different models. 
 
Table 4.4  Validation results and optimized parameter combination of 3D tomosynthesis 
classification models 
Architecture 
Batch 
size 
Learning 
rate 
Dropout 
L2 regularization 
beta 
auROC 
3D-A1 128 0.01 0.5 0.001 0.6312 
3D-T1-Alex 16 0.01 0.5 0.0001 0.6116 
3D-T2-Alex 16 0.0001 0.5 0.0001 0.6632 
 
4.3.5 Comparison of classification results of 2D mammogram and 3D tomosynthesis 
Our current results suggest that the 2D mammogram classification model performs 
slightly better than the 3D tomosynthesis classification model. However, radiologists 
generally achieve better classification accuracy on 3D tomosynthesis data. One possible 
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explanation for this phenomenon is that this study used only a subset of the 3D 
tomosynthesis frames due to memory limitations and the consistent shape requirement of 
the input. If the discarded frames contained information for diagnosing cancer that the 
selected frames lacked, then the frame sampling may have contributed to significant 
information loss. Another possible reason is that the 2D mammograms have better 
resolution than the 3D tomosynthesis data used in this study, such that the 2D 
mammograms may benefit from a higher signal-to-noise ratio [143]. 
 
4.4 Summary 
This chapter reports our work on developing and optimizing machine learning 
models for whole image classification of both 2D and 3D mammograms. We evaluated 10 
different CNN architectures and conclude that combining both data augmentation and 
transfer learning methods with a CNN is the most effective in improving classification 
performance. 
We report the first work that study both 2D and 3D mammography images for 
breast cancer classification. Our current work sheds light on how each type of dataset 
performs when trained independently. But in practice, 2D and 3D images are 
complementary to each other, where 2D offers high resolution while 3D offers multiple 
views. One of our future work is to develop an assembled classifier that integrates the 2D 
and 3D data to achieve optimal performance. 
3D tomosynthesis has proven to be much more powerful in manual detecting of 
tumors in clinical practice than conventional 2D imaging. However, 3D data is much more 
challenging to deal with, as it often corresponds to a much bigger feature space, requiring 
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a larger training dataset to obtain better performance and requiring more memory space for 
training. We believe there is still a great opportunity to improve the performance of 3D 
image classification model. We are currently collecting more images while simultaneously 
obtaining more precise annotation of each slice of 3D tomosynthesis data. Typically, only 
a few frames in 3D images of a positive exam do contain the tumor. Using negative frames 
within a positive exam may mislead the training of the model. In the meantime, we are also 
investigating alternative strategies, such as RNN model, that can leverage the sequence 
information among slices to perform classification. 
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CHAPTER 5. CONCLUSION 
In the era of big data, transformation of biomedical big data into valuable biological 
insights has become one of the most important challenges in bioinformatics. Large 
quantities of biomedical data, including DNA/RNA sequencing data, and biomedical 
imaging data, have been generated. Modern machine learning techniques, such as deep 
learning, have been widely used in extracting meaningful patterns from big data sets. This 
dissertation presents three novel machine learning applications in different but closely 
related bioinformatics domains, two of them focus on next-generation sequencing data 
analysis, and the other one is designed for biomedical imaging data analysis. 
Alternative splicing is a regulated process that enables the production of multiple 
mRNA transcripts from a single multi-exon gene. The availability of large-scale RNA-seq 
datasets has made it possible to predict splice junctions, as well as splice sites through 
spliced alignment to the reference genome. This greatly enhances the capability to decipher 
gene structures and explore the diversity of splicing variants. However, existing ab initio 
aligners are vulnerable to false positive spliced alignments as a result of sequence errors 
and random sequence matches. These spurious alignments can lead to a significant set of 
false positive splice junction predictions, confusing downstream analyses of splice variant 
detection and abundance estimation. In chapter 2, we illustrated that splice junction 
sequence characteristics can be ascertained from experimental data with deep learning 
techniques. We employed deep convolutional neural networks for a novel splice junction 
classification tool named DeepSplice. It performs better than the currently available splice 
site prediction tools. We found that there is valuable information to be gained from splice 
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junction sequences that conventional tools discard. The meaningful representations 
learning from input sequences improve accuracy. 
Metabolic reprogramming is a hallmark of cancer. In cancer cells, transcription 
factors govern metabolic reprogramming through abnormally increasing or decreasing the 
transcription rate of metabolic enzymes, which provides cancer cells growth advantages 
and concurrently leads to the altered metabolic phenotypes observed in many cancers. 
Consequently, targeting transcription factors that govern metabolic reprogramming can be 
highly effective for novel cancer therapeutics. In chapter 3, we presented TFmeta, a 
machine learning approach to uncover transcription factors that govern reprogramming of 
cancer metabolism. Our approach achieves state-of-the-art performance in reconstructing 
interactions between transcription factors and their target genes on benchmark data sets. 
Leveraging TF binding profiles inferred from genome-wide ChIP-seq experiments and 150 
RNA-seq samples from 75 paired cancerous and non-cancerous human lung tissues, our 
approach predicted 19 key TFs that may be the major regulators of the gene expression 
changes of metabolic enzymes of the central metabolic pathway glycolysis, which may 
underlie the dysregulation of glycolysis in non-small-cell lung cancer patients. 
Mammography is the most popular technology used for breast cancer early 
detection. Manual classification of mammogram images is a difficult task because of the 
variability of tumors, which yields a noteworthy number of patients being called back to 
perform biopsies, ensuring no missing diagnosis. The convolutional neural network has 
succeeded in lots of image classification challenges recent years. In chapter 4, we designed 
an approach to perform 2D mammogram and 3D tomosynthesis classification based on 
convolutional neural networks. Our study demonstrated that CNN-based models with data 
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augmentation and transfer learning have good potential for automatic breast cancer 
detection based on the mammograms and tomosynthesis data. 
All software packages of the models described in this dissertation are open-source, 
released, and freely available to the research community. 
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